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ABSTRACT

In certain aspects, the present invention provides methods and
compositions relating to a Pnmt-positive progenitor cell. In
certain aspects, the present invention relates to methods for
isolating and transplanting the subject progenitor cells, and
methods for treating diseases such as myocardiac injuries and
neurodegenerative disorders.
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PNMT AS A NOVEL MARKER FOR
PROGENITOR CELLS

(e.g., embryonic) or adult tissue/organs. In certain cases, the
subject progenitor cells differentiate into adrenergic cells. In
certain other cases, the Pnmt-positive progenitor cells transiently differentiate into adrenergic-like cells, followed by
further differentiation into cardiomyocytes, neuronal, and/or
other specialized cell types.
In one specific embodiment, the Pnmt-positive progenitor
cell is a cardiac progenitor cell (also referred to as cardiomyocyte progenitor cell). The Pnmt-positive cardiac progenitor
cell may be also positive for other markers, such as c-kit,
Sca-1, and MDRl. In certain embodiments, the progenitor
cells differentiate into a cardiomyocyte in vivo, in vitro or ex
vivo. Examples of cardiomyocytes include, but are not limited to, a pacemaker cell, such as a sinoatrial node (SAN) cell
or an atrioventricular node (AYN) cell; a His bundle (HIS)
cell; a Purkinje fiber (PUR) cell; an atrial working myocyte;
and a ventricular working myocyte. The Pnmt-positive progenitor cell can be isolated, for example, from stem cell
cultures or from developing hearts or adult hearts.
In another specific embodiment, the Pnmt-positive progenitor cell is a neural progenitor cell. The Pnmt-positive
neural progenitor cell may also be positive for other markers,
such as nestin. In certain embodiments, the progenitor cells
differentiate into a neuronal cell, such as a brainstem neuronal
cell or a retinal neuronal cell. This Pnmt-positive progenitor
cell can be isolated, for example, from stem cell cultures or
from developing brains or adult brains.
In certain embodiments, the present invention provides a
method for identifying a cardiac progenitor cell. In this
method, Pnmt expression is detected within a cell. If the cell
expresses Pnmt and differentiates into a cardiomyocyte, then
the cell is identified as a cardiac progenitor cell. Examples of
cardiomyocytes include, but are not limited to, a pacemaker
cell, such as a sinoatrial node (SAN) cell or an atrioventricular
node (AYN) cell; a His bundle (HIS) cell; a Purkinje fiber
(PUR) cell; an atrial working myocyte; and a ventricular
working myocyte. The cell may also be positive for other
markers, such as c-kit, Sca-1, andMDRl. In certain cases, the
cell is isolated from stem cell lines/cultures or from a mammalian tissue such as a developing or adult heart. In a specific
embodiment, the cell used in this method comprises a marker
gene located at one or more loci of the Pnmt gene. Thus,
expression of the marker gene recapitulates expression of
Pnmt. Cardiac progenitor cells can then be readily detected by
fluorescence-activated cell sorting (FACS), which detects the
marker expression. Useful markers include, but are not limited to, beta-galactosidase, luciferase, fluorescent proteins
such as GFP (green), BFP (blue), RFP (red), YFP (yellow),
CFP (cyan), and other suitable markers (e.g., a cell-surface
protein such as a membrane receptor).
In certain embodiments, the present invention provides a
method of inducing a Pnmt-positive cardiac progenitor cell to
differentiate into a cardiomyocyte. In this method, the Pnmtpositive cardiac progenitor cell is treated with an effective
amount of one or more agent that induces the progenitor cell
to differentiate into a cardiomyocyte. Examples of cardiomyocytes include, but are not limited to, a pacemaker cell,
such as a sinoatrial node (SAN) cell or an atrioventricular
node (AYN) cell; a His bundle (HIS) cell; a Purkinje fiber
(PUR) cell; an atrial working myocyte; and a ventricular
working myocyte. The progenitor cell may also be positive
for other markers, such as c-kit, Sca-1, and MDRl. In certain
cases, the progenitor cell is isolated from stem cell lines/
cultures or a mammalian tissue (e.g., human), such as a developing or adult heart. The agents used this method to induce
differentiation include, but are not limited to, catecholamines

RELATED APPLICATIONS
This application is a continuation of U.S. Ser. No. 11/918,
678 filed Nov. 21, 2008 now abandoned which claims priority
to PCT/US2005/010611 filed Mar. 31, 2005 which claims the
benefit of the filing dates of U.S. Provisional Application No.
60/557,785, filed Mar. 31, 2004; U.S. Provisional Application
No. 60/558,146, filed Apr. 1, 2004; and U.S. Provisional
Application No. 60/562,931, filed Apr. 16, 2004. The entire
teachings of the referenced Provisional Applications are
incorporated herein by reference in their entirety.
FUNDING
Work described herein was funded, in whole or in part, by
funds from the National Institute of Child Health Development (NICHD). The United States government has certain
rights in the invention.
SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Nov. 22, 2011, is named 1669107C.txt and is
1,126 bytes in size.
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BACKGROUND OF THE INVENTION
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Cure of a wide variety of diseases or tissue injuries by
specific replacement of damaged or malfunctional tissues by
use of totipotent, pluripotent or multipotent stem cells is on
the horizon in clinical practice (see, e.g., Fuchs, et al., 2000,
Cell, 100:143-156; Weissman et al., 2000, Cell, 100:157-168;
Blau, et al., 2001, Cell, 105:829-841). To transmute a somatic
cell into the variety of cell types needed for tissue regeneration and reconstruction in vertebrates is a realistic goal. In
fact, tissues that were formerly considered incapable of
extensive regeneration, such as brain, spinal cord, and cardiac
muscle, now appear to be capable of reconstruction functionally, at least to some extent, by stem cell populations. Stem
cells derived from the embryo and from adult tissues have
been shown to have extensive potentials for self-renewal and
differentiation.
Therefore, there is a need to develop methods of identifying or isolating stem cells for tissue reconstruction procedures. Investigation in these areas may lead to realistic
approaches in the future for stem cell therapy in a variety of
human diseases, tissue injuries, and other clinical problems.
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SUMMARY OF THE INVENTION
In certain embodiments, the present invention provides an
isolated progenitor cell that expresses phenylethanolamine
n-methyltransferase (Pnmt), referred to herein as a "Pnmtpositive" progenitor cell, including a mammalian progenitor
cell (e.g., human or mouse). The Pnmt-positive progenitor
cells can be isolated from various pluripotent stem cell cultures (e.g., adult bone marrow-derived stem cells, adiposederived stem cells, cardiac-derived stem cells, neural-derived
stem cells, embryonic stem cells, etc.), or from developing
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(norepinephrine or epinephrine), growth factors, hormones,
and extracellular matrix proteins.
In certain embodiments, the present invention provides a
method of treating a patient having a myocardial injury. In
this method, at least one (one or more) Pnmt-positive cardiac
progenitor cell is obtained and transferred into the patient,
wherein the progenitor cell differentiates into a cardiomyocyte. Typically, cells identified as Pnmt-positive cardiac progenitor cells are cultured under conditions that result in their
propagation, in order to produce a sufficient number of cells
for the desired purpose. Examples of cardiomyocytes
include, but are not limited to, a pacemaker cell, such as a
sinoatrial node (SAN) cell or an atrioventricular node (AYN)
cell; a His bundle (HIS) cell; a Purkinje fiber (PUR) cell; an
atrial working myocyte; and a ventricular working myocyte.
The progenitor cell may also be positive for other markers,
such as c-kit, Sca-1, and MD RI. In certain cases, the progenitor cell is isolated from stem cell lines/cultures or a mammalian tissue (e.g., human), such as a developing or adult heart.
Specific examples of myocardial injuries include myocardial
infarction, cardiomyopathy, and congenital heart disease.
Preferably, the progenitor cell is transferred to a damaged
cardiac region.
In a specific embodiment, the subject method further
includes expanding the Pnmt-positive progenitor cell ex vivo
before transferring progenitor cells into the patient.
In another specific embodiment, the subject method further
includes treating the patient with an immunosuppressive
agent, such as FK-506, cyclosporin or GAD65 antibodies. In
certain embodiments, expression of at least one major histocompatibility (MHC) gene (e.g., class I MHC, class II MHC,
or class I and II MHC) is inactivated in the Pnmt-positive
progenitor cell.
In certain embodiments, the present invention provides a
transplant graft comprising the subject Pnmt-positive progenitor cells. Preferably, the transplant graft does not cause
graft versus host rejection when transplanted into an animal.
In certain embodiments, the present invention provides a
method of assessing a Pnmt-positive cardiac progenitor cell
for its ability to regenerate cardiac tissues in vivo. In this
method, a Pnmt-positive cardiac progenitor cell is obtained
and transferred into a subject in need thereof. Preferably, the
transferred progenitor cell contains a marker (e.g., a fluorescent marker). Then, the transferred progenitor cell is monitored by methods, for example, magnetic resonance imaging
(MRI) or bioluminescence imaging (BLI). Useful markers
include, but are not limited to, beta-galactosidase, luciferase,
fluorescent proteins such as GFP (green), BFP (blue), RFP
(red), YFP (yellow), CFP (cyan), and other suitable markers
(e.g., a cell-surface protein such as a membrane receptor).
In certain embodiments, the present invention is a cell
comprising a marker gene located at one or more loci of a
Pnmt gene. Optionally, at least one (one or two) copy of the
Pnmt gene is deleted in the cell. Useful markers include, but
are not limited to, beta-galactosidase, luciferase, fluorescent
proteins such as GFP (green), BFP (blue), RFP (red), YFP
(yellow), CFP (cyan), and other suitable markers (e.g., a
cell-surface protein such as a membrane receptor). Preferably, the cell is a mammalian cell (e.g., human). In certain
cases, the cell is a progenitor cell.
In certain embodiments, the present invention is a method
of making the subject cell comprising a marker gene located
at one or more loci of the Pnmt gene.
In certain embodiments, the present invention relates to a
method of identifying a compound that increases expression
of Pnmt in a cell such as a progenitor cell. In this method, a
cell comprising a marker gene located at one or more loci of

the Pnmt gene is contacted with a test compound. The expression level of the marker gene in the cell is determined. If the
expression level of the marker gene is higher in the presence
of the test compound than in the absence of the test compound, the test compound is a compound that increases
expression of Pnmt. Optionally, the identified compound can
also increase the level of epinephrine in a cell. In certain
cases, the subject method further includes assessing the ability of the test compound to increase expression of Pnmt in
vivo (e.g., in an animal).
In certain embodiments, the present invention provides a
non-human transgenic animal whose genome comprises a
marker gene located at one or more loci of the Pnmt gene.
Optionally, at least one (one or two) copy of the Pnmt gene is
deleted in the animal. Exemplary markers include, but are not
limited to, beta-galactosidase, luciferase, fluorescent proteins
such as GFP (green), BFP (blue), RFP (red), YFP (yellow),
CFP (cyan), and other suitable markers (e.g., a cell-surface
protein such as a membrane receptor). For example, the transgenie animal includes mouse, rat, and rabbit.
In certain embodiments, the present invention relates to use
of the isolated Pnmt-positive progenitor cells (e.g., cardiac
progenitor cells) for treating myocardial injury in a patient.
Specific examples of myocardial injuries include myocardial
infarction, cardiomyopathy, and congenital heart disease. The
isolated progenitor cell is optionally transferred to a damaged
cardiac region.
In certain embodiments, the present invention provides a
method of delivering a scaffold graft in a target tissue, comprising: a) seeding Pnmt-positive progenitor cells onto a biocompatible scaffold, thereby forming a scaffold graft; and b)
implanting the scaffold graft from (a) in direct contact with, or
adjacent to, a target tissue for a sufficient time, wherein cells
of the target tissue associate with the implanted scaffold graft,
thereby to form new tissue.
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FIGS. lA-lC show construction and verification of the
Pnmt-Cre allele. (A) Cartoon depiction of the wild-type and
Pnmt-Cre alleles. Sequences coding for the Pnmt RNA are
depicted as an open rectangle with the direction of transcription indicated by the arrow. The thickened line shows the
Pnmt sequences used to direct the homologous recombination event that introduces the Cre-recombinase gene (Cre)
and the Neomycin resistance gene (NeoR) into Pnmt exon 1.
Cre-recombinase is fused to the Pnmt 5' UTR sequences so
that its transcription is entirely dependent upon Pnmt regulatory elements. The Cre insert contains transcriptional stop
sequences. NeoR is driven by its own promoter and the NeoR
gene is flanked with Frt sites to allow its removal via Flp
recombinase. The 5' and 3' probes used for verifying the
alleles are depicted. (B) Southern analysis of the mutated cell
lines identifies clones carrying the Pnmt-Cre insertion allele.
When digested with XbaI and Eco RI, correctly targeted cells
display an 8 kb band (5' Probe/Left Panel) or a 6 kb band (3'
probe/Right Panel) in addition to the 14 kb band indicative of
the wild-type chromosome. (C) PCR analysis described in the
Methods distinguishes homozygous wild type (+!+ ), heterozygous mutant ( +/Cre ), and homozygous mutant (Cre/
Cre) animals. RI, EcoRI; S, SacI; Xb, Xbal.
FIGS. 2A-2F show co-immunofluorescent and XGAL histochemical staining in neonatal adrenal sections in Pnmt-Cre/
R26R mice. (A) PNMT immunofluorescent histochemical
staining (FITC filters). (B) Adjacent section stained with
XGAL. (C) PNMT immunofluorescent histochemical staining of the section shown in (B) after X GAL staining. Note that

US 8,614,091 B2
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the XGAL staining blocks the fluorescent signal in co-stained
cells. (D) TH Immunofluorescent histochemical staining
(Texas Red filter) of the same section as shown in (A). (E) TH
Immunofluorescent histochemical staining of an adjacent
section (same section as shown in panels B&C) after XGAL
staining. (F) Overlay ofimages in panels D and E showing TH
Immunofluorescent and XGAL staining simultaneously.
Arrows in panels E and F indicate examples of TH+ cells that
were not stained with XGAL. Scale bar, 0.1 mm.
FIGS. 3A-3B show whole-mount XGAL staining of an
ES.5 Pnmt-Cre/R26R embryo. (A) Left ventral view. Arrow
points to Lacz+ blue-stained cells in the sinus venosus (SV)
region. Arrowheads indicate positions of additional Lacz+
cells in this heart. (B) Right dorsal view. Arrows point to
Lacz+ blue-stained cells along the dorsal crest of the neural
folds (NF). Scale bar, 1.0 mm.
FIGS. 4A-4B show whole-mount XGAL staining in El 0.5
mouse embryos. (A) Pnmt-Cre/R26R and (B) Wild-type
(Pnmt+1+)/R26R mouse embryos at El0.5. Right sagittal
views are shown. The arrow depicts the heart. Staining can
also be seen in the brainstem and 2nd branchial arch regions.
Sparse patches ofXGAL staining are also seen along the back
(dorsal surface) and in the forelimb of the Pnmt-CrexR26R
embryo. Scale bar, 1.0 mm.
FIGS. SA-SD show identification of Lacz+ cells in El0.5
mouse heart sections. (A-D) Series of sagittal sections from
left to right through an El0.5 heart from a Pnmt-Cre/R26R
embryo that was stained with X GAL and counterstained with
eosin are shown. Arrows depict areas of the heart that were
stained blue with XGAL. Abbreviations: Atr, atrial chamber,
AV, antrioventricular; OT, outflow tract SA, sinoatrial; Vent,
ventricular chamber. Scale bar, 0.1 mm.
FI GS. 6A-6D show co-immunofluorescent and X GAL histochemical staining in an E9.5 Pnmt-Cre/R26R mouse heart.
The same section is shown in panelsA-D (right sagittal view).
(A) Sarcomeric a-actinin, a myocyte-specific marker, is visualized as Texas Red fluorescent staining. (B) Bright-field
image depicting Lacz+ cells (stained blue with XGAL). (C)
Pnmt, an I CA cell marker, is seen as green (FITC) fluorescent
staining. (D) Overlay image showing all three staining patterns simultaneously. Yellow regions represent apparent costaining for sarcomeric a-actinin and Pnmt (arrows). The
arrowheads depict regions of the embryo that were stained
exclusively for Pnmt. Scale bar, 0.1 mm.
FIGS. 7A-7H show Pnmt-Cre expression in the SAN
region of E15.5 mouse hearts. Communofluorescent histochemical staining of wild-type (Pnmt+1+) E15.5 mouse
heart sections for (A) HCN4 (Arrow depicts SAN myocytes,
and arrowhead indicates presumptive AYN myocytes), and
(B) Sarcomeric a-actinin. RA, right atrium; RV, right ventricle. Scale bar, 1.0 mm. (C--H) Frontal series of E15.5
Pnmt-Cre/R26R heart sections stained for expression of Lacz
(C-E) and the pacemaker channel protein, HCN4 (panels G &
H). An expanded view of the boxed region (SAN) in panel E
is shown in panel F. Upon switching to dark-field fluorescence microscopy with FITC filters, HCN4 staining can be
seen in this section (panel G). To evaluate co-staining for
XGAL and HCN4 in this section, the images in panels F and
G were combined to produce the Overlay image depicted in
panel H. Abbreviations, Ao, aorta, Ao V, aortic valve, MiV,
mitral valve; SAN, sinoatrial node (boxed region of panels E
& F). Scale bar (for panels F--H), 0.1 mm.
FIGS. SA-SE show Lacz expression patterns in neonatal
mouse heart I: SAN region. (A) Low magnification (4x objective) frontal view of an XGAL-stained Pnmt-Cre/R26R heart
section at P2. The SAN region is boxed. Scale bar, 1.0 mm.
(B-E) Higher-magnification (20x objective) view of the

boxed region from panel A. (B) Bright-field image of blue
XGAL-stained cells in the SAN region. (C) HCN4 immunofluorescent (green) staining of the same section shown in
panel B. (D) Overlay image of panels B and C. (E) Pnmt
immunofluorescent (green) staining of an equivalent region
to that shown in panels B-D from an adjacent section. Scale
bar, 0.1 mm. Arrowheads point to the equivalent region in
each panel where Pnmt+ cells were found. Arrows in panels C
and D indicate examples of pacemaker cells co-stained for
HCN4 and XGAL.
FIGS. 9A-9H show co-immunofluorescent histochemical
staining in sagittal sections from El0.5 Dbh+1- and Dbh-1mouse embryos. (A-D) Low-magnification (!Ox objective)
view of a-actinin and HCN-4 staining in Dbh+1- (A&B) and
Dbh_;_ (C&D) embryos. The arrow indicates the presumptive
SA-node region at the mouth of the inlet to the atrial chamber.
(E-H) High-magnification (60x objective) of the SA-node
region in an adjacent section co-stained for Cx43 (E&G) and
HCN-4 (F&H) in Dbh+1- (E&F) and Dbh-1- (G&H) mouse
embryos.
FIG. 10 shows ~-adrenergic stimulation of Cx43 expression in cultured neonatal rat cardiomyocytes. The cultures
were allowed to develop spontaneous, synchronous beating
activity for 7 days prior to drug treatment. The indicated drugs
(10 µMeach) were added to the culture media from a lOOx
stock, and the cells were returned to the incubator for 5 hrs.
Protein extracts were prepared, separated by SDS-PAGE,
electro-transferred to PVDF membrane and reacted with
either an anti-Cx43 or an anti-a-actinin antibody. The blots
were developed using chemiluminescence and autoradiography. Abbreviations: Con, control (no drugs); Iso, isoproterenol; Tim, timolol; Epi, epinephrine; Cx43, connexin 43.
FIG. 11 shows comparison of action potentials recorded
from various regions of embryonic rat hearts at different
stages of prenatal development. Action potentials that were
recorded in my laboratory are shown outside the boxed region
of the E12.5 heart diagram.
FIG. 12 shows an example of optical mapping experiment
using El0.5 mouse heart. Microarray detection of action
potentials generated from a spontaneous impulse are shown
on the left, and an expanded view of selected action potentials
is shown to the right. Time of activation was estimated by
comparing the half-maximal intensity signal for each action
potential.
FIG. 13 is a schematic illustration of cardiomyocyte differentiation. This picture represents an overly simplified view
of how cardiomyocytes may differentiate from embryonic
stem (ES) cells. Alternatively, "ES cells" could be replaced
with "fertilized oocyte". The question marks in the block
arrows indicate uncertainty about the number of steps
required in between the specified cell types shown. Abbreviations, CS, cardiac stem; CMS, cardiomyocyte stem; SAN,
sinoatrial node; AYN, atrioventricular node; His, H bundle;
Pur, Purkinje fiber.
FIGS. 14A-14F are cartoon depictions of a proposed
method for molecular imaging. (A) Pluripotent recombinant
mouse ES cells (Pnmt-GFP/aMHC-Luc) are expanded in
culture, dispersed, and induced to differentiate into beating
cardiac cells using the hanging ball method. (B) During the
differentiation process, a heterogenous mixture of cells representing various developmental potentials emerges. Applicant has colored the nuclei to represent some of the expected
and observed cellular phenotypes: Black=pluripotent stem
cell (i.e., undifferentiated, as in 'A'); Grey, cardiac stem (CS)
cell (multipotent cell capable of becoming cardiac myocytes,
smooth muscle, and endothelial cells (see FIG. 13);
Green=cardiomyocyte stem (CMS) cell (identified by Pnmt-
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EGFP+ expression in nuclei-also see FIG.17); Red=beating
cardiomyocytes. There are other cell types (endothelial,
fibroblast, etc.) arising in these cultures, but only a few representative cell types are shown to illustrate the basic idea. (C)
While in culture, the cardiac--differentiated cells are loaded
with magnetic microsphere particles (for subsequent MRI in
vivo) and subjected to fluorescent-activated cell sorting
(FACS) to selectively isolate CMS (GFP+) cells loaded with
magnetic particles conjugated to a different fluorophore
("Dragon Red"). (D) These isolated CMS cells are then be
transplanted into areas of mouse hearts damaged by experimentally-induced myocardial infarction (MI), where they are
tracked in vivo over the next several days/weeks using MRI.
(E) To determine ifthe transplanted CMS cells differentiate
into cardiomyocytes in vivo, Applicant monitors the mice for
activation of the luciferase reporter gene driven from the
cardiac a-myosin heavy chain (aMHC) promoter using in
vivo bioluminescent imaging (BLI) techniques. (F) Systematic optimization of each step in this process is expected to
ultimately lead to successful repair/regeneration of damaged
cardiac muscle tissue and significant improvement in cardiac
performance (as represented by the Mighty Mouse™ picture).
FIGS. 15A-15C show effect of the catecholamine-depleting agent reserpine on the maintenance of beating rate in
neonatal rat cardiomyocyte cultures. Spontaneously beating
neonatal rat cardiomyocytes were allowed to develop for a
period of7 din culture, and different concentrations of reserpine were added directly to the culture media in each well, as
indicated. (A) Beating rates were measured at the indicated
time points in the presence of the indicated concentrations of
reserpine (n=6/group ). After the measurement at the 8-h time
point, the reserpine-containing media was removed (indicated by arrow with designation, "Drug Removal"), the cells
were rinsed with drug-free media, and replenished withdrugfree growth media. Beating rate measurements were then
re-evaluated at the 24-h time point. (B) Sample recording of
beating activity after 8 h of reserpine (2.5 µM) treatment in
one well. (C) Effect of norepinephrine (NE, 1 µM) on the
beating activity of the same cells recorded in pane B approximately 2 min after the addition of NE (before removal or
reserpine). Upper trace in panels B and C represents the
"event detector signal" used to measure rate. Lower
trace in same panels represents the actual photodiode signal. *p<0.05; **p<0.01.
FIGS.16A-16B show effects ofadrenergic antagonists on
beating rates in cultured neonatal rat cardiomyocytes. Cardiomyocytes were allowed to develop spontaneous beating
activity over a period of7 d before the addition of drugs. Each
drug was added at the indicated concentrations and beating
rates were assessed within 1-2 min after drug addition. (A)
Effect of increasing concentrations of the a 1 -selective
antagonist prazosin. (B) Effect of increasing concentrations
of the ~-selective antagonist timolol. **p<0.01 (n=6/group).
FIG. 17 shows effect of ~-adrenergic blockade on beating
rates in neonatal rat cardiomyocytes cultured using media
containing charcoal-striped serum. Neonatal rat cardiomyocytes were allowed to develop spontaneous beating activity
under normal growth conditions for a period of7 d. On d 7, the
culture media was replaced with media containing charcoalstripped serum to remove any residual catecholamines that
may have been present in the serum. Timolol (10 µM) was
added to the culture medium containing the charcoal-stripped
serum on half of the cultures at the time of media change on
d 7. Beating rates were then assessed at 24 and 72 h after drug
treatment (cells were cultured in the continuous presence of

timolol). Addition of epinephrine (1 µM) enabled full recovery of beating rate for at least 30-60 min. * * *p<0.001 relative
to control (n=6/group).
FIG. 18 shows effect of a 1 -adrenergic blockade on the
beating rates in neonatal rat cardiomyocytes cultured in
media containing charcoal-stripped serum.Application of the
a 1 -antagonist, prazosin (1 µM) resulted ina significant reduction in the beating rate compared with baseline control. This
reduction in the beating rate was reversed by the addition of
the a 1 -agonist, L-phenylephrine (L-PE) at the indicated concentrations. **p<0.01; ***p<0.001 (n=12/group ).
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The invention is based, at least in part, on Applicant's
discovery that the epinephrine biosynthetic enzyme, phenylethanolamine n-methyltransferase (Pnmt), is a novel marker
for cardiomyocyte progenitor cells in the developing heart. As
described in the working examples, Applicant created a novel
mouse model that enabled Applicant to follow the fate of
intrinsic cardiac adrenergic (ICA) cells in the developing
heart. This was accomplished through targeted insertion of
the Cre-recombinase gene into the locus encoding for Pnmt,
followed by crossing the resulting Pnmt-Cre mice with
ROSA26 reporter (R26R) mice such that expression of Lacz
(encoding ~-galactosidase) was activated in cells that were
selectively derived from the adrenergic lineage.
Pnmt is an enzyme that converts norepinephrine (NE) to
epinephrine (EPI). EPI and NE are the major circulating
catecholamines in most mammals. In adults, they are primarily produced in adrenergic neurons and adrenal chromaffin
cells by the enzymatic conversion of the amino acid, L-tyrosine. The catecholamine biosynthetic pathway is shown
below. The enzymes that catalyze each reaction are shown in
italics above the arrows between precursors and products
(TH, tyrosine hydroxylase; L-AAAD, L-aromatic amino acid
decarboxylase; DBH, dopamine ~-hydroxylase; PNMT, pheny lethanolamine N-methy ltransferase).
##S TROOOO 1##
During periods of acute stress, EPI and NE are important
modulators of"fight or flight" responses. Their actions induce
significant metabolic and physiologic responses, especially
in the cardiovascular system where they strongly increase
cardiac output by stimulating both the rate and force of cardiac contractions. NE and/or EPI are also essential for fetal
development because mice that lack the ability to produce
these neurotransmitter hormones die from cardiovascular
failure (Thomas et al., 1995, Nature 374:643-646).
In certain embodiments, the present invention relates to
identification of a population of progenitor or stem cells that
can be used in repair and/or regeneration of diseased or damaged tissue, such as the heart, brain, lungs, liver, kidney,
adrenal glands, testes, retina, and possibly other cells/tissues/
organs that have yet to be identified. Applicant's findings
indicate that the Pnmt gene can be used as a specific marker to
identify such progenitor/stem cells. These findings may significantly advance repair and regeneration studies by allowing isolation of the progenitor/stem cells easily and quickly
by using Pnmt as a specific marker for this population of cells,
which can then be used in a clinical setting to facilitate repair
and regeneration of damaged tissue.
Pnmt-Positive Progenitor Cells
In certain embodiments, the present invention provides
isolated Pnmt-positive mammalian progenitor cells. For
example, Applicant identified a subclass of cardiac cells that
have the functional and molecular characteristics of progenitor cells. In particular, these newly discovered cardiac pro-
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genitor cells are characterized by expression of Punt, and the
ability to differentiate into cardiomyocytes. The present
inventors also identified a subclass of Pnmt-positive neural
cells that are neural progenitor cells.
In certain embodiments, the Pnmt-positive progenitor cells
can be isolated from or derived from various stem cell cultures (e.g., adult bone marrow-derived stem cells, adiposederived stem cells, cardiac-derived stem cells, neural-derived
stem cells, embryonic stem cells, etc.). Alternatively, the
Pnmt-positive progenitor cells can be isolated from developing (e.g., embryonic) or adult tissue/organs. In certain cases,
the subject progenitor cells differentiate into adrenergic cells.
In certain other cases, the subject progenitor cells (defined by
their ability to express Pnmt) transiently differentiate into
adrenergic-like cells followed by further differentiation into
cardiomyocytes, neuronal, and/or other specialized cell
types.
As used herein, the term "progenitor cell" or "precursor
cell" refers to a cell that is derived from a stem cell by
differentiation and is capable of further differentiation to
more mature cell types. A "stem cell," as used herein, refers to
a cell which is capable of essentially unlimited propagation
either in vivo or ex vivo and differentiates to other cell types.
Generally, stem cells can divide without limit. After division,
the stem cell may remain as a stem cell, become a precursor
cell or progenitor cell, or proceed to terminal differentiation.
Although appearing morphologically unspecialized, the stem
cell may be considered differentiated where the possibilities
for further differentiation are limited.
As used herein, differentiation refers to the process
whereby relatively unspecialized cells (e.g., stem cells or
progenitor cells) acquire specialized structural and/or functional features characteristic of mature cells. Similarly, "differentiate" refers to this process. Typically, during differentiation, cellular structure alters and tissue-specific proteins
appear.
In certain specific embodiments, the invention provides
compositions or formulations comprising a Pnmt-positive
progenitor cell and a physiologically compatible carrier. As
used herein, "physiologically compatible carrier" refers to a
physiologically acceptable diluent such as water and physiologically compatible buffers (e.g., phosphate buffered
saline, Hank's solution, Ringer solution, or physiologically
buffered saline).
In one embodiment, the invention provides Pnmt-positive
progenitor cells for a variety of applications, including but not
limited to, cellular replacement therapy for myocardial injuries and neurodegenerative disorders. The Pnmt-positive progenitor cells of the invention can also be used to carry out
gene therapies in isograft, allograft or xenograft transplantations. As used herein, "allogeneic" refers to genetically different members of the same species; "isogeneic" refers to
individuals of identical genetic constitution; and "xenogeneic" refers to members of a different species.
In another embodiment, the Pnmt-positive progenitor cells
described herein can be used to produce recombinant cells,
artificial tissues, and replacement organs in culture. They can
also be used for the ex vivo production of catecholamines
such as adrenaline (epinephrine). Molecular characteristics
of the subject Pnmt-positive progenitor cells, such as cardiac
progenitor cells, can be used in various diagnostic, pathological, or investigative procedures to identify, localize, and quantitate progenitor cells in tissues from a patient or experimental
animal.
In certain embodiments, the present invention relates to
methods of identifying Pnmt-positive progenitor cells, such
as cardiac progenitor cells. Progenitor cells of the present

invention can be identified by their expression of Pnmt (e.g.,
by FACS, immunocytochemical staining, RT-PCR, Southern
Northern and Western blot analysis, and other such techniques of cellular identification as known to one skilled in the
art).
For example, immunocytochemical staining can be carried
out according to the following method. Heart tissues or cells
are incubated with a primary antisera to the Pnmt protein. The
antisera is rinsed off with PBS and incubated with the appropriate fluorescently labeled secondary antisera. Fluorescence
microscopy is then performed to identify Pnmt-positive progenitor cells. Antisera useful according to the invention
include monoclonal and polyclonal antibodies.
RT-PCR and Southern blot analysis are well known in the
art. To illustrate, total cellular RNA prepared from heart tissues or cells is reverse-transcribed and amplified by PCR for
about 35 cycles depending on the desired degree of amplification. The RNA samples are then either PCR-amplified with
oligonucleotide primers for RT-PCR or probed with oligonucleotide probes for subsequent Southern blot hybridization. Sequences of the oligonucleotides are considered to be
within the scope of the art. As a general guide, primers are
selected from two different exons and encompass at least one
intronic sequence of the Pnmt gene.
Methods of Isolation and Transplantation
In certain embodiments, the present invention relates to
methods of isolating and transplanting Pnmt-positive progenitor cells, such as cardiac progenitor cells. As described
above, the Pnmt-positive progenitor cells can be isolated from
various pluripotent stem cell cultures (e.g., adult bone marrow-derived stem cells, adipose-derived stem cells, cardiacderived stem cells, neural-derived stem cells, embryonic stem
cells, etc.), or from developing (e.g., embryonic) or adult
tissue/organs (e.g., heart). The isolated progenitor cells can
then be expanded ex vivo and the resulting cells transplanted
back into the donor as an isograft. In the donor, the transplanted Pnmt-positive progenitor cells may differentiate to
provide, for examples, cardiomyocytes to replace cardiomyocytes such as those lost due to myocardial injury.
"Isolating" a progenitor cell refers to the process of removing a progenitor cell from a tissue sample and separating away
other cells which are not progenitor cells of the tissue. An
isolated progenitor cell is generally free from contamination
by other cell types and generally has the capability of propagation and differentiation to produce mature cells of the tissue
from which it was isolated. However, when dealing with a
collection of progenitor cells, e.g., a culture of progenitor
cells, it is understood that it is practically impossible to obtain
a collection of progenitor cells which is 100% pure. Therefore, an isolated progenitor cell can exist in the presence of a
fraction of other cell types which do not interfere with the
utilization of the progenitor cell for analysis or production of
other, differentiated cell types. Isolated progenitor cells are
generally at least 30%, 40%, 50%, 60%, 70%, 80%, 85%,
90%, 95%, 98%, or 99% pure. Preferably, isolated progenitor
cells according to the invention are at least 98% or at least
99% pure.
A progenitor cell is "expanded" when it is propagated in
culture and gives rise by cell division to other progenitor cells.
Expansion of progenitor cells may occur spontaneously as
progenitor cells proliferate in a culture or it may require
certain growth conditions, such as a minimum cell density,
cell confluence on the culture vessel surface, or the addition of
chemical factors such as growth factors, differentiation factors, or signaling factors.
A progenitor cell or differentiated cell is transplanted or
introduced into a mammal when it is transferred, for example
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from a culture vessel into a subject (individual or patient).
Transplantation, as used herein, can include the steps of isolating a progenitor cell according to the invention and transferring the progenitor cell into a subject Transplantation can
involve transferring a progenitor cell into a subject by injection of a cell suspension into the subject, surgical implantation of a cell mass into a tissue or organ (e.g., heart) of the
subject, or perfusion of a tissue or organ with a cell suspension. The route of transferring the progenitor cell or transplantation is determined by the need for the cell to reside in a
particular tissue or organ and by the ability of the cell to find
and be retained by the desired target tissue or organ. In the
case where a transplanted cell is to reside in a particular
location, it can be surgically placed into a tissue or organ or
simply injected into the bloodstream ifthe cell has the capability to migrate to the desired target organ.
In certain embodiments, the present invention relates to
methods of overcoming the problems of immune rejection
resulting from transplantation of tissue. In one embodiment,
the use of isografted progenitor cells makes it possible to alter
the transplanted cells to render them or less likely to cause
immune reaction. A further advantage of using progenitor
cells, rather than an intact heart, is that transplanted progenitor cells can differentiate in situ and better adapt to the host
environment. Another embodiment of the invention contemplates the use of partially differentiated progenitor cells ex
vivo, for example, to form progenitor cells, which are subsequently transplanted into the host, with further differentiation
taking place within the host.
In a specific embodiment, Pnmt-positive progenitor cells
of the invention are immunologically blind or immunoprivileged. For example, immunoprivileged progenitor cells do
not express sufficient amounts of class I and/or class II major
histocompatibility (MHC) antigens (also referred to as HLA
or human leukocyte antigen) to elicit an immune response
from the host. Progenitor cells obtained from allogeneic or
xenogeneic sources do not initiate a host versus graft response
in immunocompetent transplant recipients.
As a non-limiting example, Pnmt-positive progenitor cells
are isolated, cultured, and maintained in vitro. They can be
obtained from tissue or from existing stem cell lines. Using
genetic engineering techniques, the Pnmt-positive progenitor
cells are engineered to express a reporter gene, such as
enhanced green fluorescent protein (EGFP), beta-galactosidase gene, firefly luciferase gene, or other similar type of
reporter, from the endogenous Pnmt locus. Differentiation of
the progenitor cells is then initiated along pathways leading to
the preferential development of specific cell and tissue types
(e.g., cardiac, neural, renal, pulmonary or hepatic). Pnmtlinked reporter gene expression are used to isolate specific
progenitor cells using fluorescence-activated cell sorting
(FACS) or other methodology following induction of differentiation towards specific cell types in vitro. The Pnmt-positive cells are transplanted into or near damaged or diseased
tissues. Targeted disruption of one or both Pnmt alleles does
not appear to be detrimental, which is an advantage of using
Pnmt as a marker. To avoid cell/tissue rejection, expression
from the major histocompatibility (MHC) locus can be disrupted. Alternatively, the nuclear transfer technique can be
employed to convert recipient progenitor cells into host cells
by replacing the progenitor cell nuclei with nuclei isolated
from the individual destined to receive the transplant. Typically, the nuclear transfer step is performed prior to engineering the progenitor cells to express a reporter gene from the
Pnmtlocus.

Methods of Molecular Imaging
In certain embodiments, the present invention provides
methods of assessing a Pnmt-positive cardiac progenitor cell
for its ability to regenerate cardiac tissues in vivo. For
example, in such methods, a Pnmt-positive cardiac progenitor
cell is obtained and transferred into a subject in need thereof.
The fate of the transferred progenitor cell is then monitored in
vivo. In certain cases, the transferred progenitor cell contains
a marker, such as GFP, luciferase, and beta-galactosidase. To
illustrate, the transferred progenitor cell can be monitored
(tracked) by magnetic resonance imaging (MRI) or by bioluminescence imaging (BLI).
Development and application of non-invasive imaging
techniques to physically and functionally assess the potential
of novel cardiac progenitor cells to regenerate damaged myocardium has clear clinical significance. Repair and replacement of damaged cardiac muscle tissue is a key limitation in
the prognosis for recovery from ischemic and other forms of
heart disease. There is a great need for new approaches to this
enduring problem, since heart disease is the leading killer in
the United States. New strategies for regenerating damaged
cardiac muscle could be readily translated to the clinical
setting if first shown to be effective in animal models.
Accordingly, the present invention relates to use of
molecular imaging techniques in vivo to evaluate the novel
progenitor cell-based strategy for cardiac regenerative medicine. Specifically, this application contemplates methods for
detecting and quantifying molecular and cellular pathways
that regulate heart function, and methods for cell tracking in
vivo for applications in cell-based therapeutics. For example,
cardiac progenitor cells of the invention can be transplanted
into damaged hearts and these cells can be tracked in vivo
using modified magnetic resonance and bioluminescent
imaging methods.
One specific embodiment of the invention is a method of
identifying and selecting cardiac progenitor cells based on
their ability to express knock-in reporter genes from the
endogenous Pnmt gene locus. These cells can be isolated in
vitro, loaded to magnetic microsphere particle beads, and
transplanted into regions of the heart damaged by myocardial
infarction. Thus, another embodiment of the invention provides methods of molecular imaging of cardiomyocytes progenitor cells (the method is also referred to as cardiac imaging) to track and study the functional development of these
novel progenitor cells in vivo. Optionally, the subject methods of cardiac imaging are performed in small animals.
In certain embodiments, the present invention includes
application of non-invasive molecular and cellular imaging
techniques that would facilitate development and characterization of progenitor cell strategies in the heart because they
permit repeated assessments of the transplanted cells in vivo
without the need to sacrifice the animals or subject them to
complicated invasive procedures. Several different in vivo
imaging approaches have been developed, such as MRI and
BLI.
MRI has been used for many years to assess anatomical and
physiological parameters in vivo; however, the use of MRI to
follow (track) specific cell populations in the cardiovascular
system has only recently been described in a few published
reports. Of particular interest for Applicant is the discovery
that it is possible to "load" cells with magnetic nanoparticles
(e.g., ferrodex) in vitro and track these cells with MRI after
they have been transplanted into the heart (or other organs/
tissues) in vivo. Remarkably, cells loaded with these magnetic particles appear to be relatively stable in vivo, which
makes it possible to track transplanted cells over several days,
weeks, and perhaps months.
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In contrast to MRI, BLI technology is primarily based on
the ability to detect light emitted from expression of the firefly
luciferase reporter gene in the presence of the substrate,
luciferin. Although this technology has been used for many
years as a way to quantitate reporter gene activity in transiently transfected cells in vitro, only recently has it been
adapted for in vivo imaging applications. Several studies
have, for example, demonstrated that luciferase activity can
be detected in anesthetized mice using a specialized ccd videocamera set-up ina darkroom. To date, most of these studies
have fused a strong viral promoter to drive high levels of
luciferase activity in target tissues. Certain embodiments of
the invention contemplate fusion of strong cell type-specific
promoters to luciferase so that the differentiation state of
transplanted cells can be assessed by evaluating activation of
luciferase expression over time in vivo using BLI.
Methods of Treatments
In certain embodiments, the present invention provides
methods of preventing or correcting developmental defects
(e.g., cardiac or neuronal), or treating complications (conditions, disorders or diseases) arising later in life. Such methods
involve administering to a subject in need thereof the Pnmtpositive progenitor cells of the invention.
In one embodiment, the Pnmt-positive progenitor cells of
the invention are useful to replace lost cardiomyocytes or to
increase the overall numbers of cardiomyocytes in patients
suffering from a myocardiac injury. Myocardial injury refers
to damage to the muscle or the "myocardium" in the wall of
the heart as a result of disease or trauma. Myocardial injury
can be attributed to many things, such as cardiomyopathy,
myocardial infarction, or congenital heart disease.
A "cardiomyocyte" is a cell of the cardiac muscle that is
striated like skeletal muscle, having microscopically visible
myofilaments arranged in parallel with the sarcomere. Cardiac muscle can generate its own excititory impulses from the
sino-atrial node, which acts like a biological pacemaker. In
this manner, the contracting signal for cardiac muscles originates in the heart itself. However, the autonomic nervous
system can exert control over how fast the signals form and
propagate through the heart, which regulates the rate of myocardial contraction.
Cardiomyopathy refers to any disease or dysfunction of the
myocardium (heart muscle) in which the heart is abnormally
enlarged, thickened and/or stiffened. As a result, the heart
muscle's ability to pump blood is usually weakened. The
disease or disorder can be, for example, inflammatory, metabolic, toxic, infiltrative, fibroplastic, hematological, genetic,
or unknown in origin. There are two general types of cardiomyopathies: ischemic (resulting from a lack of oxygen) and
non-ischemic. Ischemic cardiomyopathy is a chronic disorder caused by coronary artery disease-a disease in which
there is atherosclerotic narrowing or occlusion of the coronary arteries on the surface of the heart. Coronary artery
disease often leads to episodes of cardiac ischemia, in which
the heart muscle is not supplied with enough oxygen-rich
blood. Eventually, the heart muscle enlarges from the additional work it must do in the absence of sufficient oxygen-rich
blood.
Congenital heart disease refers to a condition that is present
at birth and often as the heart is forming even before birth.
Congenital heart disease may affect the heart, the heart's
valves, the veins leading to, or the arteries leading away, from
the heart, or the connections between these parts of the body.
Accordingly, in certain embodiments, the present invention provides methods of treating or preventing heart disorders such as cardiomyopathy, myocardial infarction, congenital heart disease, heart failure, and any kind of cardiac

dysfunction. Heart failure generally refers to the inability of
the heart to supply sufficient oxygenated blood to meet the
metabolic needs of the tissues and cells in an individual. This
can be accompanied by circulatory congestion, such as congestion in the pulmonary or systemic veins. As used herein,
the term heart failure encompasses heart failure from any
cause, and is intended herein to encompass terms such as
"congestive heart failure," "forward heart failure," "backward
heart failure," "high output heart failure," "low output heart
failure," and the like. Conditions that could lead to heart
failure include, but are not limited to, coronary artery disease,
cardiomyopathy, or congenital heart disease.
Cardiac dysfunction is understood to include any impairment in the heart's pumping function. This includes, for
example, impairments in contractility, impairments in ability
to relax (sometimes referred to as diastolic dysfunction),
abnormal or improper functioning of the heart's valves, diseases of the heart muscle (sometimes referred to as cardiomyopathy ), diseases such as angina and myocardial ischemia
and infarction characterized by inadequate blood supply to
the heart muscle, infiltrative diseases such as amyloidosis and
hemochromatosis, global or regional hypertrophy (such as
may occur in some kinds of cardiomyopathy or systemic
hypertension), and abnormal communications between
chambers of the heart (for example, atrial septa! defect). See
Braunwald, Heart Disease: a Textbook of Cardiovascular
Medicine, 5th edition 1997, W B Saunders Company, Philadelphia Pa. (hereinafter Braunwald).
In another embodiment, the Pnmt-positive progenitor cells
of the invention are useful to replace lost neuronal cells or to
increase the overall numbers of neuronal cells in individuals
in order to treat neurodegenerative disease (disorder or condition) and neurological trauma. Examples of neurodegenerative diseases include, but are not limited to, Huntington's
Disease (HD), Alzheimer's Disease (AD), and Parkinson's
Disease (PD). The Pnmt-positive progenitor cells can be
transplanted into any area from which neural progenitor cells
can be obtained that serves to restore function to a degenerated area of the host's nervous system, particularly the host's
central nervous system (CNS). To illustrate, suitable areas
include the cerebral cortex, cerebellum, midbrain, brainstem,
spinal cord and ventricular tissue.
In certain embodiments, the present invention relates to use
of Pnmt-positive progenitor cells that are immunologically
blinded or immunoprivileged, such that in allogeneic or xenogeneic transplants, they are recognized as self by the recipient, and are not MHC restricted by class I or class II antigens.
For example, these cells do not express MHC class I and/or
class II antigens. Alternatively, progenitor cells isolated from
a non-human mammal according to the invention are transplanted into a human subject. Prior to the transplantation step,
the progenitor cells may be cultured, and/or expanded and/or
differentiated.
In certain embodiments, the progenitor cells of the invention can be treated by gene therapy to correct a genetic defect
and introduced into a patient to restore cardiac or neuronal
function.
In one embodiment of the invention, the Pnmt-positive
progenitor cells can be differentiated either in culture or in
vivo by applying one or more growth factors, or other treatments such as transfection with a nucleic acid molecule, that
results in differentiation of the progenitor cells to cardiomyocytes or neuronal cells.
In another embodiment of the invention, the Pnmt-positive
progenitor cells can be transplanted without any ex vivo treatment and the appropriate growth factors can be provided in
situ within the patient's body. In yet another embodiment, the
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progenitor cells can be treated with growth factors or other
agents ex vivo and subsequently transplanted into the patient
in a partially differentiated or terminally differentiated state.
Other aspects of the invention include methods oftransfecting progenitor cells, dosages and routes of administration,
pharmaceutical compositions, donor-isograft protocols, and
immunosuppression methods.
The invention specifically contemplates transplanting into
patients isogeneic, allogeneic, or xenogeneic progenitor
cells, or any combination thereof.
Mode of Administration
In certain embodiments, the present invention provides
methods of treating a disease or a tissue injury by delivering
the Pnmt-positive progenitor cell to a diseased or injured
target tissue (e.g., heart). In certain specific aspects, the
present invention provides composition and methods of tissue
engineering. Tissue engineering provides the opportunity to
generate living substitutes for tissues and organs, which may
overcome the drawbacks of classical tissue reconstruction.
Optionally, the method can be used alone or in combination
with other therapies.
In one embodiment, the present invention provides a tissue
engineering composition which comprises: a) a Pnmt-positive progenitor cells; and b) a biocompatible scaffold. Such
tissue engineering composition generates a scaffold graft to
be delivered to a target tissue.
In certain embodiments, the present invention provides a
method of delivering a scaffold graft in a target tissue, comprising: a) seeding the Pnmt-positive progenitor cell onto a
scaffold, thereby forming a scaffold graft; and b) implanting
the scaffold graft from (b) in direct contact with, or adjacent
to, a target tissue for a sufficient time, wherein cells of the
target tissue associate with the implanted scaffold graft,
thereby to form new tissue. For example, the scaffold graft
can be delivered in a heart tissue by surgical implantation.
Optionally, such methods may further comprise removing the
scaffold graft from the subject. For example, the scaffold graft
removed from the subject (i.e., the scaffold and the tissue it
bears at the end of the implantation period) can then be
re-grafted into another target tissue.
As described herein, the biocompatible scaffold can consist of bioresorbable or non-bioresorbable materials. If the
scaffold consists of a single bioresorbably material, it is preferably one that does not significantly resorb during the period
of time when the target tissue is being laid down on or within
it. Such scaffolds generate a scaffold graft that includes living
cells and essentially retain their shape and mechanical integrity. In some instances, it may be preferable to use scaffolds
containing bioresorbable materials that lose, for example,
less than a 2% of their weight during the same period. If the
scaffold is constructed with two or more bioresorbable materials, it may be preferable to select the bioresorbable material
that provides the scaffold with its structural integrity according to these criteria.
In certain embodiments, the bioresorbable materials for the
biocompatible scaffold include bioresorbable polymers or
copolymers that comprise the following monomers or mixtures of polymers and/or copolymers formed thereby:
hydroxy acids, particularly lactic acid; glycolic acid; caprolactone; hydroxybutyrate; dioxanone; orthoesters; orthocarbonates; aminocarbonates.
Optionally, the bioresorbable materials can also include
natural materials such as collagen, cellulose, fibrin, hyaluronic acid, fibronectin, chitosan, or mixtures of two or more
of these materials. The bioresorbable materials may also
comprise devitalized xenograft and/or devitalized allograft.
Bioresorbable ceramics can also be included within the scaf-

fold. Bioresorbable materials are well known in the art,
including, for example, poly(lactic acid), poly(glycolic acid),
polydioxanone, polyhydroxybutyrate, and poly(trimethylene
carbonate), or mixtures thereof. Poly(lactic acid) has good
mechanical strength and does not resorb quickly. Thus, its
mechanical properties can be retained for a time sufficient for
tissue in-growth to occur (at which point the tissue can
assume some, if not all, of the load-bearing function of the
scaffold (see A. G. A. Coombes and M. C. Meikle, "Resorbable Synthetic Polymers as Replacements for Bone Graft,"
Clinical Materials, 17:35-67, 1994).
Non-bioresorbable materials are also well known in the art,
including, for example, polyesters, particularly aromatic
polyesters, such as polyalkylene terephthalates; polyamides;
polyalkenes such as polyethylene and polypropylene; poly
(vinyl fluoride), polytetrafluoroethylene carbon fibres; silk
(natural or synthetic); carbon fibre; glass; and mixtures of
these materials. An advantage of non-bioresorbable materials
is that they essentially retain their initial mechanical properties.
In certain embodiments, the biocompatible scaffold can
include certain additional components. For example, the scaffold may include bioactive factors, such as growth factors,
hormones, catecholamines (norepinephrine or epinephrine),
extracellular matrix proteins, cytokines or chemokines.
In other embodiments, hydrogels can also be included in
the biocompatible scaffold. For example, the hydrogel can be
incorporated within and/or around the scaffold prior to
implantation to facilitate the transfer of cells and other biological material (e.g., growth factors) from the surrounding
tissue into the scaffold. Hydro gels include positively charged,
negatively charged, and neutral hydrogels, and can be either
saturated or unsaturated. Examples of hydrogels are
TETRONICS™ and POLOXAMINES™, which are poly
(oxyethylene)-poly(oxypropylene) block copolymers of ethylene diamine; polysaccharides, chitosan, poly(vinyl
amines), poly(vinyl pyridine), poly(vinyl imidazole), polyethylenimine, poly-L-lysine, growth factor binding or cell
adhesion molecule binding derivatives, derivatized versions
of the above (e.g., polyanions, polycations, peptides, polysaccharides, lipids, nucleic acids or blends, block-copolymers or
combinations of the above or copolymers of the corresponding monomers); agarose, methylcellulose, hydroxyproylmethylcellulose, xyloglucan, acetan, carrageenan, xanthangum/locust beangum, gelatine, collagen (particularly
Type 1), PLURONICS™, POLOXAMERS™, POLY(N-isopropylacrylmide), and N-isopropylacryhnide copolymers.
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The following materials and methods were used in carrying
out the work described herein. The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely
for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit
the invention.
Example 1
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PNMT is a Novel Marker for Cardiomyocyte Progenitor
Cells
1. Introduction
Epinephrine (EPI) and norepinephrine (ME) are the major
peripheral catecholamines produced in mammals. They are
synthesized via the enzymatic conversion of dopamine to NE
by the action of dopamine ~-hydroxylase (Dbh) and, subse-
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quently, of NE to EPI by the action of phenylethanolamine
n-methyltransferase (Pnmt) (Cooper et al., 1991, Norepinephrine and Epinephrine. In The biochemical basis ofneuropharmacology, (New York: Oxford University Press), pp.
220-284). In adult mammals, this synthesis occurs primarily
in the adrenal medulla and in the sympathetic nervous system.
Mice that lack the ability to produce NE and EPI due to
targeted disruption of the Dbh gene die in utero from apparent
cardiac failure (Thomas et al., 1995, Nature 374, 643-646).
The vast majority of Dbh mouse embryos die before the
adrenal gland even forms and before maturation of the sympathetic nervous system, suggesting that the primary
source(s) of catecholamine biosynthesis in the embryo must
be different from that in adult mice (Thomas et al., 1995,
Nature 374, 643-646). One potential source is the heart itself,
where Applicant and others have shown that ICA cells are
present beginning at relatively early stages (E9 .5 in rat; E3 in
chick) of cardiac development (Ignarro and Shideman, 1968,
J. Pharmacol. Exp. Ther. 159, 38-48; Ebert et al., 1996, J.
Mo!. Cell. Cardiol. 28, 1653-1658; Huang et al., 1996, J. Clin.
Invest 98, 1298-1303; Ebert and Thompson, 2001, Circ. Res
88, 117-124 ). A specific developmental role for these ICA
cells remains elusive, but Applicant has recently shown that
they are transiently and progressively associated with regions
of the heart that become pacemaking and conduction tissue
(Ebert and Thompson, 2001, Circ. Res 88, 117-124 ). This
association was initially observed in the sinoatrial node
(SAN) and atrioventricular canal (AVC) regions at approximately embryonic day 11.5 (El 1.5) in the rat The clustering
of ICA cells in these regions then declined over the next
several days of development, but re-appeared along the crest
of the ventricular septum (bundle of His region) and, somewhat more sporadically, trailing down the ventricular septum
towards the apex at approximately El6.5. These patterns of
ICA cell distribution were transient, lasting not more than a
1-2 days in each of these locations. It was not clear if this
progressive appearance and disappearance of ICA cells in
these various cardiac regions was due to migration, differentiation, and/or death ofICA cells.
To help resolve these possibilities, Applicant has <leveloped a mouse genetic model for studying the fate and function
of adrenergic cells in vivo. Specifically, the Cre-recombinase
gene was inserted into the endogenous Pnmt locus (PnmtCre) so that Cre-recombinase expression would be directed
by Pnmt regulatory DNA sequences. Upon crossing these
Pnmt-Cre mice to the reporter R26R strain of mice, Applicant
anticipated activation of Lacz expression exclusively in adrenergic cells via Cre-mediated recombination of upstream
1oxp sites flanking a DNA sequence responsible for blocking
transcription of the Lacz gene (Soriano, 1999, Nat. Genet. 21,
70-71). In this system, lacZ expression does not require the
continuous activation of Pnmt-Cre. Rather, the genetic
changes induced at the Rosa26 locus by transient expression
of the Cre-recombinase permanently mark the altered cells
and their descendants as ~-galactosidase positive and, therefore, provide a means to follow the fate of adrenergic derived
cells throughout development In addition, because the targeted insertion of Cre recombinase disrupted the expression
of the Pnmt gene, Applicant could assess the potential consequences of selective adrenergic deficiency in these mice.
This is the first report to demonstrate that targeted disruption
of Pnmt gene expression leads to EPI deficiency, and it is also
the only study to show that the fate of adrenergic cells can be
effectively mapped in vivo. These efforts have led to the
rather surprising and novel finding that adrenergic cells contribute much more extensively to myocardial development
than previously appreciated.

2. Results
To determine whether epinephrine plays an important role
during development and to identify adrenergic cell descendants in the developing mouse, Applicant inserted the Crerecombinase gene into the mouse Pnmt locus so the expression of Cre-recombinase would be dependent upon Pnmt
regulatory sequences (FIG. lA). Specifically, Applicant
inserted the Cre-recombinase gene into exon 1, creating a
gene fusion of the 5' leader sequences from Pnmt directly to
Cre-recombinase open reading frame. This strategy was
designed to disrupt functional expression of Pnmt while permitting expression of Cre-recombinase exclusively in adrenergic cells. Verification of the correct targeting of the Crerecombinase insert was confirmed by Southern blotting using
5' and 3' probes each external to the targeting vector (FIG.
lB).
Two of the correctly targeted clones were further propagated and introduced into mouse blastocysts, and independent lines of founder mice were produced. These founder
mice were crossed with wild type C57B/6 females to generate
Fl animals used in all subsequent studies. Germ-line transmission of the Pnmt-Cre allele was verified initially by Southern blotting and then by PCR (FIG. lC). When Fl heterozygotes were intercrossed, mice harboring the disrupted Pnmt
allele were born in normal Mendelian ratios. 35+/+:75+/-:
46-/- were the actual numbers of mice born as compared
with 39, 78, and 39 mice expected for each genotypic class
from 156 total progeny (P value=0.410 using the Chi square
test). The-/- mice appear overtly normal and are fertile even
in -/-x-/- crosses.
The absence of Pnmt expression was predicted to result in
mice that cannot produce epinephrine. To test this hypothesis,
Applicant measured epinephrine (EPI) and norepinephrine
(NE) concentrations in adrenal extracts from Pnmt+1+,
Pnmt+!Cre, and Pnmtcre!Cre mice by radioimmunoassay
(Table 1). EPI was not detectable in extracts from Pnmtcreicre
mice, and the concentration of NE was found to be significantly greater in Pnmtcreicre relative to Pnmt +!+ and
Pnmt+!cre extracts (P<0.001). In contrast, NE and EPI concentrations were similar in extracts from Pnmt+1+ and
Pnmt+!cre mice. These results show that targeted insertion of
Cre recombinase effectively disrupted Pnmt expression and
production ofEPI in homozygous Pnmtcreicre mice, but that
heterozygous Pnmt+!cre mice were indistinguishable from
wild-type (Pnmt+1+) mice in terms of adrenal NE and EPI
content.
TABLE-US-00001 TABLE 1 Adrenal catecholamine content
(pg/ng protein). Genotype NE EPI Pnmt+/+ (n=5) 14.2.+-.0.6
24.6.+-.2.9 Pnmt+!Cre (n=l 0) 17 .8.+-.1.4 25.0.+-.2.8
Pnmtcre!Cre (n=4) 32.8.+-.2.6*** n.d. n.d. not detected
(<0.004 pg/ng) ***p<0.001 compared to Pnmt+1+ and
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To map the developmental distribution of Pnmt-Cre-expressing cells and their descendants, mice heterozygous for
the insertion (Pnmt+/cre) were mated with R26R mice,
homozyogous at the ROSA26 reporter locus. Cells in R26R
mice have the ability to robustly express the bacterial Lacz
(~-galactosidase) gene if activated by Cre-recombinase (due
to removal of a floxed transcriptional block) (Soriano, 1999,
Nat. Genet. 21, 70-71). To determine if applicant's system
was working, Applicant first examined ~-galactosidase staining in adrenal glands where the expression patterns of Pnmt
are well-documented and relatively simple. As illustrated in
FIG. 2A, Pnmt Immunofluorescent staining is concentrated in
the adrenal medulla. An adjacent section stained with XGAL
to detect Lacz expression (blue cells) produced a nearly
identical pattern of staining (FIG. 2B). When Pnmt immunofluorescent staining was performed on this section after the
XGAL staining, little or no fluorescently-stained cells were
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observed because the XGAL blocked or quenched the fluorescence in co-stained cells (FIG. 2C). Thus the localization
of Pnmt and ~-galactosidase appear to be completely coincident here. As a control, the same sections were also stained for
Th to independently identify chromaffin cells (FIGS. 2D, E,
F). Th staining was similar to Pnmt and XGAL staining in
these sections, but there were a few cells that stained positively for Th that were not stained with XGAL (FIGS. 2E&F,
arrows). These Th+LacZ- cells presumably represent the
minority of chromaffin cells that are known to be noradrenergic ratherthan the adrenergic majority (Coupland and Tomlinson, 1989, Int. J. Dev. Neurosci. 7, 419-43; Ebert and
Thompson, 2001, Circ. Res 88, 117-124). Together, these
results demonstrate that Lacz expression was highly selective
in adrenal sections where it was confined to adrenergic
(Pnmt+) cells.
To evaluate Pnmt-Cre expression in the developing mouse
embryo, applicant performed whole-mount staining with
XGAL. The earliest stage of development when Lacz expression could be detected was embryonic day 8.5 (E8.5). Lacz
expression was observed in the heart (FIG. 3A) and along the
dorsal ridges of the neural folds in the region of the midbrainhindbrainjunction (FIG. 3B). Within the heart, there appears
to be a small cluster of Lacz+ cells in the sinus venosus region
(FIG. 3A, arrow), with a few additional Lacz+ cells apparent
in the ascending loop and also near the atrioventricular junction (see arrowheads, FIG. 3A).
Over the next two days, Lacz expression became much
more widespread in the heart, as shown in FIG. 4A. By this
time, Lacz expression was also evident in the brainstem
region, 2nd branchial arch, and sporadically along the dorsal
surface of the embryo. Lacz expression was dependent upon
Cre-recombinase expression from the Pnmt locus since none
was observed when wild-type embryos were similarly
crossed with R26R mice (FIG. 4B).
Although it appears from the whole-mount staining (FIG.
4A) that the entire heart was expressing Lacz at this stage of
development, examination of heart sections from these
embryos revealed that the true staining pattern was more
restricted (FIG. 5). Sporadic staining of cardiac cells was
observed in the atrial and ventricular regions, including cells
in the trabecular region of the ventricle. As shown in FIG. 5,
Lacz expression was observed in the SA junction region
(FIG. 5A-B); however, the strongest Lacz staining was found
near the AV and conoventricular junction regions (FIG.
5C-D). These Lacz expression patterns were consistently
observed at this stage of development, and they appear similar
to the pattern of catecholamine-producing cells previously
reported at a comparable developmental stage in the rat (Ebert
and Thompson, 2001, Circ. Res 88, 117-124).
The pattern of Lacz expression in the heart appears to be
restricted to myocardial cells. To further evaluate this observation, Applicant performed triple-labeling experiments
whereby Pnmt-Cre/R26R heart sections (E9.5) were stained
for expression of (i) a muscle-specific marker, sarcomeric
a-actinin (red fluorescence, FIG. 6A), (ii), Lacz as a marker
for cells descended from an adrenergic lineage (blue XGAL
staining, FIG. 6B) and (iii) an adrenergic cell marker, Pnmt
(green fluorescence, FIG. 6C). Extensive overlap of these
three staining patterns could be observed by merging the
individual staining panels into a single "overlay" image, as
shown in FIG. 6D. The yellow regions represent cells that
co-express a-actinin and Pnmt (arrows point to some
examples of overlapping expression patterns). Some cells are
clearly red or green, but many yellow cells can also been seen
in this image. Notably, most of the exclusive green (Pnmt+/
a-actinin) cells in the overlay image (FIG. 6D) were found

just outside the heart, in both the anterior region adjacent to
the outflow tract as well as in the posterior region adjacent to
the atrial chamber (indicated by the arrowheads, FIG. 6C-D).
The Lacz+ cells (blue) were again found concentrated at
junction regions, specifically between the atrial, ventricular,
and outflow tract cavities.
By El5.5, the heart has matured morphologically to
assume its adult-like appearance. To determine if Pnmt-expressing cells contribute to pacemaker cells in the sinoatrial
node (SAN), Applicant performed a preliminary immunofluorescent histochemical staining analysis of wild-type El 5 .5
mouse embryo sections using an antibody that recognizes the
Hyperpolarization-activated cyclic nucleotide-modulated
channel isoform 4 (HCN4), a major pacemaker channel protein expressed in the SAN (Garcia-Frigola et al., 2003, Gene
Expr. Patterns. 3, 777-783; Stieber et al., 2003, Proc Natl.
Acad. Sci. USA 100, 15235-15240). As shown in FIG. 7A,
HCN4 staining is highly restricted to the SAN region of the
right atrium (arrow), and to a lesser extent, the AYN region
(arrowhead). In contrast, sarcomeric a-actinin was found to
be expressed throughout the myocardium in this section (FIG.
7B). These data confirm that HCN4 was localized to pacemaker cells in the developing mouse heart.
As shown in the series of sections from a Pnmt-Cre/R26R
embryo, Lacz expression not only persists in the heart at
El 5.5, but is highly pervasive throughout the myocardium in
all four chambers (FIG. 7C-E). By far, the strongest and most
extensive labeling was found in the ventricular septum, with
the most prominent staining appearing at the crest of the
septum and extending laterally into both ventricular chambers along the base as well as caudally down the septum
towards the apex. Lacz expression in the free walls of both
chambers was considerably more sparse than that found in the
septum, with a tendency to be localized in cells near the
endocardial surface, though Lacz+ cells were also clearly
seen in the mid- and epicardial regions of the ventricular
myocardium. There appeared to be little or no Lacz expression in the aorta (Ao), aortic valves (Ao V), and mitral valves
(MiV), all of which can be clearly seen as non-stained tissue
in FIG. 7D; however, the myocardial region immediately
adjacent to the intake region of each of these valves was
strongly labeled with blue XGAL stain.
Within the atria, Lacz expression was sporadic, with the
majority of atrial myocytes appearing as non-stained cells.
The exception to this pattern of atrial staining appeared in the
sinoatrial node (SAN) region where a strong clustering of
blue Lacz+ cells was evident (FIGS. 7 E & F). To show that
these cells were SAN myocytes, Applicant performed immunofluorescent histochemical staining of the sections with the
anti-HCN4 antibody. As shown in FIGS. 7G & H, HCN4
expression is robust in this region and overlaps extensively
with the XGAL staining. These results demonstrate that
many, but not all, of the presumptive pacemaker cells
(HCN4+) in the SAN also expressed Lacz in these Pnmt-Cre/
R26Rmice.
Although Lacz expression is found in pacemaker cells as
Applicant has just shown, it is clear from the data presented
thus far that Lacz expression in the heart extends well beyond
the SAN region. By El 5.5, most of the Lacz-expressing cells
are found throughout the myocardium, as indicated above
(see FIG. 7C-E).
This pattern of Lacz expression persisted in the heart
through at least the early postnatal period. As shown in FIG.
8, extensive XGAL labeling was observed throughout the
heart, and was especially dense in the ventricular septum.
Many of the pacemaker cells (HCN4 +)were also stained blue
with XGAL (FIG. SB-D). Endogenous Pnmt expression in
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the SAN region was extremely weak at this stage of development (Postnatal day 2, P2), being at best confined to a small
cluster of cells (see arrowhead, FIG. SE).
3. Materials and Methods
A) Creation of Pnmt-Cre Knock-in/Knockout Mice
To construct targeting vector pKP506 Applicant first isolated and subcloned a 7 kb Sad fragment from bacterial
artificial chromosome 238M20 (Genome Systems). This
fragment carries Pnmt exon 1 and includes 3 .3 kb upstream of
the ATG initiation codon and also 3. 7 kb of sequences 3' of the
translation start site. A 1.4 kb SexAl fragment carrying exon
1 was next subcloned and mutagenized using the Gene Editor
Mutagenesis Kit (Promega) to add a unique EcoRI site in
place of the normal Pnmt translation initiation codon. A cassette carrying the Cre-recombinase gene fused to a nuclear
localization signal (NLS) was then inserted at this unique
EcoRI site so that the expected mRNA product is a fusion of
the Pnmt 5' untranslated leader to sequences encoding the
Cre-recombinase protein. The cassette also included NeoR
sequences flanked by FRT recombination sites. This modified
SexAI fragment was then exchanged with its wild-type cognate on the Sad clone. Finally the diptheria toxin A gene
(DT-A) was added adjacent to the 5' Pnmt flank for negative
selection.
Forty-five micrograms of linearized vector DNA were
electroporated into Rl mouse embryonic stem cells. G418resistant clones were isolated and their DNAs characterized
by Southern blotting using probes external to the targeting
vector (FIG. 1). Cells from two positive clones were injected
into C57BL/6 blastocysts and chimeric mice from these
injections were mated to C57BL/6 females. Genotypes at the
Pnmt locus were identified by PCR analysis using the following primers: Primer 21 (5'-CAGGCGCCTCATCCCTCAGCAGCC-3', SEQ ID NO: 1); Primer 22 (5'-CTGGCCAGCGTCGGAGTCAGGGTC-3', SEQ ID NO: 2); and
Primer 23 (5'-GGTGTACGGTCAGTAAATTGGACACCGTCCTC-3', SEQ ID NO: 3). These amplification reactions
yield products of 200 and of 160 bp for the wild-type and the
mutant alleles, respectively. Pnmtcrei+ mice were then intercrossed or mated to R26R reporter mice as described in the
text.
B) Catecholamine Radioimmuno-Assays
Epinephrine and norepinephrine concentrations were measured by radioimmunoassay as described previously (Ebert
and Thompson, 2001, supra). Briefly, adrenal glands were
isolated from decapitated neonates and immediately frozen
on dry ice. Individual adrenal gland extracts were prepared by
sonication for 10 sec in 0.1 M HCI, followed by microcentrifugation (14,000xg, 10 min) to remove residual debris. The
extracts were assayed using a commercially available radioimmunoassay (ALPCO Labs, Inc., Wyndham, N.H.), and
protein concentrations were determined using the Bio-Rad
(Hercules, Calif.) protein assay. Equivalent amounts of protein (5 ng/sample) were assayed in a volume of 0.25 mis.
Results are expressed as Mean.+-.S.E.M. and compared for
statistically significant differences by one-way analysis of
variance (ANOVA) with p<0.05 required to reject the null
hypothesis.
C) Whole-Mount Staining for ~-Galactosidase Activity
Embryos were staged by timed matings. Females carrying
a vaginal plug were removed from the mating cage and noon
of that day was considered to be E0.5. Isolated embryos were
fixed 50 minutes at 4.degree. C. in PBS containing 2%
paraformaldehyde (w/v) and 2% glutaraldehyde (v/v).
Embryos were rinsed at 4.degree. C. with PBS three times for

30 minutes each and then incubated in PBS containing
mg/ml XGAL (5-bromo-4-chloro-3-indoyl-beta-Dpyranoside), 5 mM ferricyanide, 5 mM ferrocyanide, 2 mM MgCl 2 ,
and 0.2% Ipegal CA-630 (Sigma). After 15 hours at
30.degree. C., the embryos were rinsed in PBS containing 3%
DMSO and then stored at 4.degree. C. in PBS.
D) Immunofluorescent Histochemical Staining
Co-immunofluorescent histochemical staining was performed essentially as described previously (Ebert and
Thompson, 2001, supra). Primary antibodies used in this
study include rabbit polyclonal antibodies from Chemicon
International (Temecula, Calif.) that selectively recognize
either Pnmt (ABllO) or HCN4 (AB5808), and mouse monoclonal antibodies from Sigma-Aldrich (St. Louis, Mo.) that
selectively recognize either Th (T1299) or sarcomeric a-actinin (A7811 ). Fluorescently-tagged secondary antibodies
were obtained from Jackson Immunolabs (Denver, Pa.), and
include fluorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG and Texas Red-conjugated donkey antimouse IgG. All antibodies were used at 1: 100 dilution, except
for the anti-HCN4 antibody, which was used at 1:50 dilution.
Embryos were isolated from timed-pregnant females and
fixed with freshly prepared 4% paraformaldehyde in 0.1 M
phosphate buffered saline, pH 7.3 for 1-2 hours on ice. The
samples were then transferred to 30% sucrose solution in
PBS, pH 7 .3, and allowed to equilibrate at 4.degree. C. for at
least 48 hours. The sucrose-saturated samples were then
shipped to FD Neurotechnologies, Inc. (Catonsville, Md.) for
sectioning (20 µm) and mounting onto SuperFrost Plus
microscope slides (Fisher Scientific, Inc., Pittsburgh, Pa.).
The sections were then frozen and stored at -SO.degree. C. for
subsequent use.
To perform the immunostaining procedure, the slides were
first thawed at room temperature, and each section was ringed
with a PAP pen (Research Products International, Mount
Prospect, Ill.) to form an incubation well. The tissues were
then rehydrated with PBS for 20 minutes, followed by incubation with blocking solution (0.3% Triton X-100, 5% powdered nonfat dry milk, and 0.02% sodium azide in PBS) for
20-30 minutes at room temperature. The blocking solution
was then replaced with fresh blocking solution containing the
primary antibody (for co-staining, two different primary antibodies were included in the same incubation solution). Primary antibody incubations proceeded for one hour at room
temperature and then overnight at 4.degree. C. in a humidified
chamber. Following this incubation period, the primary antibody solutions were removed and the sections washed three
times (10 minutes each) in PBS at room temperature. All
remaining steps were performed at room temperature. Fluorescently-tagged secondary antibodies were incubated with
the sections for 2 hours at room temperature in the dark. The
secondary antibody solutions were then discarded and the
sections washed in three successive changes of PBS. Slides/
coverslips were mounted with VectaShieldmounting medium
(Vector Laboratories, Burlingame, Calif.).
For experiments where XGAL staining and immunofluorescent labeling were combined, Applicant first performed
the XGAL staining on the sections overnight as described
above. The XGAL solution was then removed, and the sections were washed with PBS (3xl 0-mins each) prior to initiating the immunofluorescent staining as described in the preceding paragraph. Digital images were collected using a
Nikon Eclipse El 000 fluorescence microscope, and processed for display using Adobe Photoshop 5 .5 software.
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Example 2

(from Chemicon International, Inc., Temecula, Calif.) in this
assay to determine if it can serve as a useful marker for this
experiment. HCNl is known to be expressed in the developing heart (Shi et al., 1999, Circ Res 85:el-e6), presumably in
pacemaker cells (Mangoni et al., 2001, Cardiovasc Res
52:51-64). The existing markers likely provide informative
results regarding coexpression of catecholamine biosynthetic
enzymes and pacemaker proteins.
Another experiment is to evaluate Pnmt-GFP knock-in
expression in the developing mouse heart. The objective is to
determine if expression of GFP faithfully reproduces the
pattern of the endogenous Pnmt gene. The rationale is that
GFP expression should recapitulate PNMT expression since
Applicant has inserted the GFP reporter gene into the mouse
Pnmt locus.Applicant expects to find GFP-expressing cells in
the embryonic mouse heart clustered around pacemaking and
conduction centers. It is likely that GFP expression in these
mice aids to identify, isolate, and characterize living cardiac
adrenergic cells as described above.
To obtain embryos that are heterozygous forthe Pnmt-GFP
allele, homozygous Pnmt-GFP males are mated with wildtype females. The embryos are isolated at various embryonic
stages, fixed, processed, and sectioned for immunohistochemical staining experiments. Initially, Applicant examines them for expression of GFP using laser-scanning confocal fluorescence microscopy. If GFP expression patterns are
reflective of those that Applicant has observed for endogenous PNMT in the developing heart, then Applicant initiates
co-staining experiments to help verify that GFP expression is
confined to Pnmt-expressing cells. To accomplish this, Applicant uses a rabbit anti-PNMT primary antibody with a Texas
Red-conjugated anti-rabbit secondary antibody. Thus, this
strategy should allow Applicant to visualize PNMT in the red
spectrum and GFP in the green spectrum. Applicant can then
overlay the images obtained from each wavelength separately
to evaluate the degree of overlapping expression.
Another experiment is to isolate and carry out electrophysiological characterization of cardiac adrenergic cells.
The objective of this experiment is to characterize the electrophysiological properties of cardiac adrenergic cells. The
rationale is that, if adrenergic cells are also pacemaker cells,
then Applicant should expect to find spontaneous action
potential generation similar to that observed in SA-nodal
cells. In addition, pacemaker currents should be expressed in
these cells, while inward rectifiers (e.g., IKZ) are not expected
to be found in these cells (Mangoni et al., 2001, supra).
Cells are isolated from Pnmt-GFP embryonic mouse
hearts, and seeded onto collagen-coated glass coverslips for
analyses using whole-cell patch-clamp recording techniques.
Applicant patches the fluorescent cells from the mixed population of GFP+ and GFP- heart cells seeded onto the coverslips. Applicant utilizes established protocols to measure
action potentials, pacemaker (IF) and other cardiac ion currents Clea' L, lea' T, INa' etc.). If GFP-expressing cells are
difficult to find, applicant can selectively enrich for them
using fluorescence-activating cell-sorting (FACS) strategies.
Alternatively, applicant uses the Pnmt-Cre/LacZ mice. In
general, the Pnmt-Cre/LacZ mice can serve as a back-up
model for essentially all of the experiments that Applicant is
proposing with the Pnmt-GFP mice. It is possible, for
example, to isolate living Lacz+ cells by pre-incubating them
with a fluorescent substrate, fluorescein dl-~-galactoside
(FDG) and then using FACS to isolate the Lacz+ cells (Fiering et al., 1991, Cytometry 12:291-301).
Another experiment is to perform gene expression
profile(s) of cardiac adrenergic cells. The objective is to identify genes uniquely expressed in cardiac adrenergic cells. The

Roles of Catecholamines in Cardiac Development
The goal of this Example is to understand how catecholamines influence heart development. Genetic studies have
shown that catecholamines are essential for proper embryonic development because mice lacking the ability to produce
noradrenaline (norepinephrine) and adrenaline (epinephrine)
die from apparent cardiovascular failure in utero (Thomas et
al., 1995, supra). The specific function of catecholamines in
cardiac development, however, has not been elucidated.
Applicant's research has shown that the heart itselfis a source
of epinephrine production at early stages of development
(Ebert et al., 1996, supra), and that epinephrine-producing
cells are transiently clustered in pacemaking and conduction
centers (SA node, AV node, His bundle, ventricular septum)
(Ebert and Thompson, 2001, supra). These findings have
prompted applicant to propose that catecholamines are essential for cardiovascular development because they stimulate
pacemaking activity and facilitate the differentiation of conduction tissue. Three specific aims are described as follows:
Specific aim 1 is to identify and characterize adrenergic
cells in the embryonic mouse heart. This aim is to test the
hypothesis that catecholamine-producing cells are pacemaker cells in the embryonic mouse heart. The following
experiments are carried out.
One experiment is to perform co-immunofluorescent staining for adrenergic and pacemaker markers. The objective is to
determine if catecholamine biosynthetic enzymes (i.e.,
PNMT, DBH, and TH) are expressed in pacemaker cells in the
embryonic mouse heart. The rationale is that, if adrenergic
cells are pacemaker cells, then Applicant should expect to
find them in pacemaker regions of the developing mouse
heart, as Applicant has seen in the embryonic rat heart. Further, pacemaking proteins (e.g., HCN1&4 channel proteins)
and catecholamine biosynthetic enzymes (PNMT, DBH, and
TH) would be expected to be co-expressed in the same cells.
Applicant utilizes dual immunofluorescent histochemical
staining techniques to study the temporal and spatial expression patterns of catecholamine biosynthetic enzymes and
pacemaker proteins in the developing mouse heart. The staining is performed essentially as described in Example 1.
Embryos are isolated from timed-pregnant wild-type mice at
E7.5, ES.5, E9.5, El0.5, E12.5, E14.5, and E18.5, and processed for immunofluorescent histochemical staining. An
outline of the co-staining strategy is depicted in Table 2.
TABLE-US-00002 TABLE 2 Co-immunofluorescent histochemical staining strategy outline. Primary antibody pairs
Secondary antibodies Rabbit anti-PNMT+Mouse anti-TH+
FITC-conjugated Donkey Mouse anti-a-actinin*anti-rabbit
IgG+ Texas Red-conjugated Donkey anti-mouse IgG Rabbit
anti-DBH+Mouse anti-TH+Same as above Mouse anti-aactinin*Rabbit anti-HCN4+Mouse anti-TH+Same as above
Mouse anti-a-actinin* Rabbit anti-HCNl+Mouse anti-TH+
Same as above Mouse anti-a-actinin* *Adjacent serial sections are co-stained for the myocyte marker, a-actinin, and
the indicated rabbit antibody.
As shown in FIG. 9, the anti-HCN4 antibody selectively
identifies presumptive SA nodal cells in the embryonic mouse
heart. The specificity of the anti catecholamine biosynthetic
enzyme antibodies (TH, DBH, and PNMT) has already been
described (see Ebert & Thompson, 2001, supra). In addition,
the use of an antisarcomeric a-actinin antibody as a marker
for working myocardial cells is well-established. Thus, using
these selective marker antibodies, Applicant determines if
catecholamine biosynthetic enzymes are expressed in SA
nodal cells. Applicant also tests a new anti-HCNl antibody
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rationale is that Applicant's hypothesis predicts that cardiac
adrenergic cells become pacemaker/conduction system myocytes. Applicant expects to find gene expression signatures
for pacemaker (HCN) and other cardiac ion charmel proteins
(e.g., subunits of charmels responsible for gating Ifl INa' lea'
L, lea' T, and IKr-all of which have recently been shown to
be present in mouse SA nodal cells) (Mangoni et al., 2001,
supra). The results of this experiment can identify genes that
are uniquely or preferentially expressed in ICA cells, potentially providing novel information about how these cells
develop and function.
GFP+ cells are isolated from El0.5 Pnmt-GFP knock-in
mouse hearts by enzymatic/mechanical dissociation of
embryonic hearts into single cells (Maltsev et al., 1994, Circ.
Res. 7 5 :233-244) that are separated into GFP+ and GFP- cell
populations using FACS. RNAs are purified from the isolated
cells and analyzed usingAffymetrix mouse expression chips.
Expression patterns for cardiac adrenergic cells (GFP+) are
compared to non-adrenergic cardiac cells (GFP-).
Applicant has recently performed a pilot gene chip screen
using RNA isolated from neonatal rat cardiomyocytes that
had been cultured for 10 days in the absence and presence of
adrenergic receptor blockers (timolol and phenoxybenzamine, 10 µMeach). The samples were analyzed using the
Affymetrix Rat Genome U34A GeneChip®, containing 8799
gene fragments that represent all full-length or armotated
genes. Interestingly, connexin 43 expression was decreased
by -65% following adrenergic receptor blockade. Cx43 is
mentioned only because Applicant has other corroborating
data indicating that its expression may be positively influenced by the presence of catecholamines (FIGS. 9-10). Any
interesting leads are pursued by first replicating the experimental results, and then using independent, conventional
assays such as Northern and Western blots, to confirm (or
refute) the gene-chip data (for selected genes).
Specific aim 2 is to map the fate of cardiac adrenergic cells
in the developing mouse heart. This aim is to test the hypothesis that catecholamine-producing cells are the progenitors of
cardiac pacemaking and conduction system myocytes in the
mouse. The following experiments are carried out.
One experiment is to localize Pnmt-Cre/LacZ expression
in developing mouse heart. The objective is to identify and
map the fate of adrenergic cells in the developing mouse
heart. The rationale is that, if adrenergic cells contribute to the
development of the pacemaking/conduction system of the
heart, then Applicant might expect to find them preferentially
localized to regions of the heart that give rise to the SA-node,
AV-node, Bundle of His, and Purkinje fibers.
Applicant crosses Pnmt-Cre mice with R26R mice to create embryos that express Lacz only in Pnmt-expressing cells.
For early embryonic stages (E7 .5-E12.5), whole-mount ~-ga
lactosidase staining is performed. Positive staining is
intensely blue. Staining patterns are documented using digital
photomicroscopy. The stained embryos are then be sectioned,
counterstained with eosin, and re-photographed at low and
high magnification. Because of diffusion concerns in the
larger later stage embryos (E13 and later), whole-mount
staining is not performed with them. Instead, isolated
embryos or tissues (e.g., heart, adrenal glands) are first fixed
and sectioned prior to staining for ~-galactosidase. Staining
patterns are compared with published histological and anatomical evaluations of mouse cardiac development.
It is clear that Lacz expression in Pnmt-Cre/R26R
embryos is not restricted exclusively to pacemaking and conduction centers. The proximal components of the pacemaking/conduction system-i.e., SA node, AV node, and bundle
of His regions appear to be included in the ~-gal staining

results obtained with these mice, but Applicant has not seen
any evidence for Lacz localization in Purkinje fibers. If an
association with the proximal pacemaking/conduction centers is maintained in the mice, then Lacz expression in PnmtCre/R26R mice could represent a molecular marker that may
be used to distinguish between proximal and distal components of the pacemaking/conduction system in the developing
heart. Alternatively, Applicant may find that adrenergic cells
and their descendents (Pnmt-Cre/LacZ+) are simply in the
vicinity of developing pacemaking/conduction centers at certain stages of development, but that they are not actually the
pacemaking/conduction myocytes themselves. This issue
should be clarified by successfully completing the following
co-immunofluorescent staining experiment.
Another experiment is to perform co-immunofluorescent
histological staining to identify specific cell types. The objective is to identify the specific cardiac cell type( s) that produce
catecholamines in the developing heart. The rationale is that
ifapplicant' s hypothesis is correct, then developing SA nodal
cells should be Lacz+ in embryos from Pnmt-CrexR26R
matings. Applicant's preliminary data suggest that ICA cells
are found in pacemaking/conduction system tissue as well as
in other parts of the heart. The results from the proposed
experiments should provide cell type-specific identification
of cells that are ICA descendents. This information is potentially important because it is likely to provide novel insight
about fundamental aspects of cardiac development and function.
Applicant performs dual immunofluorescent histochemical staining for ~-gal and various cell type-specific markers.
Applicant first verifies that ~-gal expression occurs in ICA
cells by co-staining embryonic sections with anti-~-gal and
anti-catecholamine biosynthetic enzyme antibodies. To identify specific cell types, Applicant proposes to use the antibodies listed in Table 3 below.
TABLE-US-00003 TABLE 3 A list of cell type specific antibodies. Cell Type Target Antigens Antibody Source Intrinsic
Cardiac PNMT Rabbit anti-PNMT Ebert Adrenergic (ICA)
cells TH Mouse anti-TH Sigma ICA+Descendents ~gal
Mouse anti-~gal Sigma ICA+Descendents ~gal Rabbit anti~gal Chemicon or Hoechst Cardiomyocyte Sarcomeric a-actinin Mouse anti-a-actinin Sigma Pacemaker cells HCN4
pacemaker Rabbit anti-HCN4 Chemicon channel Conduction cells* Connexins (Cx43, Mouse anti-Cx43 Sigma Cx40,
and Cx45) Rabbit anti-Cx40 & Cx45 Thompson Neural crest
cellsAP-2transcript. factor Rabbit anti-AP-2 Santa Cruz Biotech Proepicardial and a4-Integrin Mouse anti-a4 integrin
Chemicon neural Rabbit anti-a4 integrin crest cells Endothelial cells PECAM Rat anti-PECAM Pharmingen Smooth
muscle cells a-sm. muscle actin Mouse anti-aSMA Sigma
*Conduction cells are actually a heterogeneouos collection of
cells that express various gap junction proteins (connexins).
Each connexin is expressed in a specific non-uniform pattern
in the developing heart. Cx43 is most widespread, while Cx40
becomes largely restricted to atrial tissue, and Cx45 is most
prevalent in pacemaking and conduction nodes.
Another experiment is to examine proliferative activity of
cardiac adrenergic cells. The objective is to determine if cardiac adrenergic cells proliferate in the developing mouse
heart. The rationale is that terminally differentiated cardiomyocytes are thought to be largely post-mitotic. Applicant
anticipates that cardiac adrenergic cells may represent a transient cardiac phenotype, and they ultimately differentiate into
pacemaking and conduction system myocytes. As such,
Applicant finds that unlike mature cardiomyocytes, cardiac
adrenergic cells still retain proliferative capabilities.
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Applicant uses the bromodeoxyuridine (BrdU) labeling
strategy for labeling DNA-synthesizing cells in the developing heart (see, e.g., Cheng et al., 1999, Development 126:
5041-5049). Each animal will receive two IP injections of
bromodeoxyuridine (160 mg BrdU/kilogram body weight)
two hours apart, followed by euthanasia and sacrifice four
hours after initial injection, for a total labeling period of 4
hours. Hearts will be immediately removed, flushed with
heparinized saline for retrograde aortic perfusion, and fixed
by perfusion with methanol/DMSO (80/20). Formaldehyde
fixation, as needed for other antibody staining, will require
retrieval of BrdU antigenicity with 2N HCl, now routine.
Alternatively, if two or three channel immunofluorescence of
other markers would be useful, DNA-replicating cells may be
labeled with 3 H-5-methyl-thymidine (IP) for autoradiographic colocalization with fluorescent markers (see, e.g.,
Sedmera et al., 2002, Anat Rec 267:137-145).
Another experiment is to examine migration capability of
cardiac adrenergic cells. The objective is to determine if cardiac adrenergic cells migrate. The rationale is that data from
the immunofluorescent and ~-gal staining experiments indicate that cardiac adrenergic cells may arise from proepicardium and neural crest, two highly migratory cell types (see
e.g., Li et al., 2002, Development 129:2031-2042; Maschhoff
and Baldwin, 2000, Am J Med Genet. 97:280-288). Migration of cardiac adrenergic cells is likely to be detected.
Proepicardial and branchial arch regions of the Pnmt-GFP
embryos are isolated at E9.5-E10.5 and explanted onto collagen-coated coverslips, cultured and assayed as described by
Li et al., 2002, supra). Fluorescent (e.g., GFP-expressing)
cells are recorded using fluorescence-based time-lapse video
microscopy. Similar assays are performed with enzymatically-dissociated cells isolated from Pnmt-GFP mouse hearts
between E8.5 and El 1.5. In both assays, Applicant calculates
the distance traveled and speed of migration. Fluorescent
beads are included in the cultures to provide fixed reference
points.
Specific aim 3 is to evaluate the development of pacemaking/conduction tissue function in the absence and presence of
norepinephrine and epinephrine. This aim is to test the
hypothesis that norepinephrine and/or epinephrine are
required for functional development of the cardiac pacemaking/conduction system. The following experiments are carried out.
One experiment is to examine pacemaker/conduction
marker expression.+-.catecholamines. The objective is to
determine ifthe expression of pacemaker (HCN4) and conduction (Cx43) system markers is altered in the absence of
endogenous catecholamines (Dbh-1- mice) relative to their
expression in catecholamine-competent (Dbh+/+ or Dbh+1-)
embryos. The rationale is that, ifNE and/or EPI are necessary
for pacemaker/conduction system development, then Applicant expects to find altered expression patterns for HCN4,
Cx43, and/or additional pacemaker/conduction system markers in catecholamine-deficient hearts.
Applicant compares the expression patterns of HCN 4 and
Cx43 in catecholamine-deficient (Dbh_1_) and normal
embryos (Dbh+1-) obtained from parental crosses of Dbh+1malexDbh-1- female (to preclude rescue of embryonic lethality by maternal sources of NE/EPI). Development of heterozygous (Dbh+1-) embryos appears completely normal
with no associated embryonic lethality. Thus, Applicant compares HCN4 and Cx43 expression in Dbh-1- and Dbh+1embryos from the same litters between E8.5 and El0.5, the
developmental period immediately preceding the onset of
lethality in Dbh-1- embryos. This strategy can be expanded to
include other markers as they become available and as war-

ranted by results from the earlier experiments and/or relevant
reports published by other groups.
The Dbh knockout mouse model originally described by
Thomas et al. (1995, supra) are used for this experiment.
Although Dbh-1- embryos die of cardiovascular failure in
utero, they can be rescued by administration ofDOPS in the
maternal drinking water (note that DOPS can be converted to
NE in vivo by an alternative pathway). After birth, DOPS is no
longer needed for survival or reproduction, so it is completely
feasible to generate Dbh_;_ dams for this experiment (see
FIG. 9). The Dbh gene, not the Pnmt or Th genes, is the key
knockout target for this experiment. As describe above,
homozygous disruption of Pnmt resulted in loss of EPI production in the developing mouse, but this did not result in any
observed lethality or overt phenotype. Thus, EPI is not essential for cardiovascular development (provided that NE is
present). On the other hand, loss ofEPI and NE is an embryonic lethal phenotype, with Dbh_;_ mice dying between
El0.5 and E13.5 (Thomas et al., 1995, supra).
Applicant already has Dbh_;_ mice and is establishing a
small breeding colony of these animals for use in this and
subsequent experiments. One alternative strategy would be to
selectively eliminate NE/EPI production from cardiac cells
using a cardiac-specific Cre-recombinase gene that is
expressed at early stages of cardiac development in adrenergic cells.
Another experiment is to evaluate pacemaker activity.+.catecholamines. The objective is to determine if intrinsic
pacemaking activity is altered by the absence of endogenous
catecholamines, beating rates are measured from wild-type
and catecholamine deficient embryonic hearts under physiologic conditions. Receptor-specific adrenergic drugs are
employed to help identify the subtype( s) of adrenergic receptors involved in mediating these responses. The rationale is
that, if endogenous catecholamines stimulate pacemaking
activity, thenApplicant should find that Dbh_;_ embryos have
slower heart rates than their wild-type siblings. This has
already been demonstrated to some extent, though the measurements were performed at room temperature rather than at
37.degree. C. Applicant plans to extend these initial findings
by carefully comparing rates at 37.degree. C. in the absence
and presence of various adrenergic drugs. NE/EPI or ~-ago
nists should rescue/recover rates. Alpha-adrenergic drugs
may also show some activity. Conversely, beating rates in
wild-type embryos may be sensitive to adrenergic receptor
blockade. Catecholamines can act acutely on pacemaker cells
since their absence (Dbh-1- mice) did not appear to alter
pacemaker channel expression. Hence, the cellular pacemaker "machinery" appears to be in place, but it still may
need some external stimulation by NE/EPI to operate efficiently (e.g., to sufficiently maintain cardiac output at early
pre-innervation stages of development).
Applicant sets up matings between Dbh_;_ females and
Dbh+1- males to generate offspring that are -50% Dbh-1(embryonic lethal between E10.5-E13.5) and -50% Dbh+/(indistinguishable from wildtype ). The embryos are isolated
at El0.5 and placed in pre warmed, oxygenated, serum-free
culture media (DMEM) for assessment of beating rates in an
incubation chamber equipped with an inverted phase-contrast
microscope with an attached video camera. The embryos are
equilibrated in the culture media under physiological conditions for at least 20-30 mins prior to performing beating rate
assessments. Photodiode sensors positioned on the video
screen detect light changes that occur as result of cardiac
contractions, and these signals are converted to electrical
signals that are acquired and analyzed using National Instruments' data acquisition hardware and software (customized
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LabView 4.0 software). Beating rates are recorded from one
embryo at time, and Applicant first obtains a baseline rate
before evaluating drug effects. The baseline rate is recorded
over 5-10 mins. prior to the addition of indicated drug, as
outlined in Table 4 below. The drugs are evaluated over a
broadrange of concentrations (e.g., 0, 0.01, 0.1, and 1 µM) by
progressively increasing the amounts of drug administered to
each sample.
TABLE-US-00004 TABLE 4 Outline of drug-testing strategy
for beating rate assessments. Drug Receptor Specificity
Genotype to be tested Epinephrine Nonselective agonist
Dbh-1- Norepinephrine Semi-selective agonist Db!P- (poor
~ 2 agonist Isoproterenol Nonselective ~ agonist Dbhl- Terbutaline Selective ~ 2 agonist Dbh-1- Phenylephrine Selective
a 1 agonist Dbh_;_ Timolol Nonselective ~ Wild-type and
antagonist heterozygotes (Dbh+1-) Atenolol Selection ~ 1
antagonist Wild-type and heterozygotes (Dbh+1-) Phenoxybenzamine Nonselective a Wild-type and antagonist heterozygotes (Dbh+1-) Prazosin Selective a 1 antagonist Wildtype and heterozygotes (Dbh+1-)
Another experiment is to identify regional action potential
(AP) characteristics (conventional microelectrode). The
objective is to determine if the absence of endogenous catecholamines alters the generation and/or propagation of electrical signaling in the heart. The rationale is that different
regions of the developing heart have characteristic types of
action potentials associated with them. If endogenous catecholamines are required to stimulate and help to coordinate
electrical signaling activity in the developing heart, then
altered action potential profiles in catecholamine-deficient
embryos can be detected.
Dbh_;_ and Dbh+/- embryos are isolated at El0.5, decapitated, and placed in a pre-warmed, oxygenated incubation
chamber. Using conventional microelectrode recording techniques, Applicant records transmembrane voltages from
three regions-atrial, ventricular, and outflow tract. Applicant compares the upstroke velocity, duration, and shape of
the action potentials recorded from these specific cardiac
regions. As an initial test of the feasibility of this approach,
Applicant isolated E12.5 rat embryos and recorded action
potentials from different regions of the heart, as shown in
FIG. 11. These results, represented by the action potential
traces drawn outside the boxed regions in FIG.11, are similar
to those published previously (shown inside the boxes with
corresponding heart diagrams for each age).
Another experiment is to perform optical mapping of
action potentials using photodiode array detection. The
objective is to measure conduction velocity in the absence
and presence of endogenous catecholamines. The rationale is
that rapid and directed propagation of electrical signals
through the myocardium is critical for the development and
maintenance of cardiac performance. If catecholamines are
required to stimulate the development of the conduction systern, then Applicant might expect to find significantly slower
conduction velocities and altered vector directions in catecholamine-deficient embryos.
To evaluate propagation of the conduction signal through
the developing heart, Applicant uses voltage-sensitive dyes
and optical (photodiode arrays) imaging techniques to simultaneously record action potentials from many locations and
map the direction of conduction in the heart as has been
elegantly described in Rentschler et al., 2001, Development
128: 1785-1792; Rentschler et al., 2002, Proc Natl Acad Sci
USA 99: 10464-10469). Applicant has performed some preliminary tests of this experimental strategy using El0.5
mouse hearts in short-term (1-5 hrs) culture. The hearts were
stained with di4-ANEPPs, a fluorescent voltage-sensitive

dye, and both spontaneous and stimulated electrical activity
were recorded using a photodiode array (FIG. 12). In this
initial experiment, Applicant estimated the conduction velocity to be -0.16 mm/msec. The data showed that the signal-tonoise ratio is very large(> 10), indicating that the technique is
capable of measuring the propagating velocity on a small
spatial scale (-20 µm).
Another experiment is to carry out cap junction assays.+.catecholamines. The objective is to determine if gap junction
development is impaired in embryonic hearts from catecholamine-deficient mice. The rationale is that Applicant's preliminary studies suggest that gap junction (Cx43) expression
is impaired in Dbh_;_ embryos. Gap junction deficiency could
compromise the ability of the developing heart to effectively
transmit electrical signals through the myocardium, resulting
in poor conduction and coordination of electrical activity in
the heart. There is also some pharmacological evidence suggesting that gap junction activity can be regulated through
adrenergic signaling pathways (for review, see Dhein, 1998).
If Applicant can show that gap junction activity is significantly decreased in Dbh-1- embryonic hearts relative to
Dbh+/- or Dbh+/+ hearts, then such a result would strongly
support the data showing that Cx43 expression is reduced in
embryos deprived ofNE/EPI.
Applicant uses a variation of the fluorescent dye-coupling
assays described by Li et al. (2002, supra) andAi et al. (2000,
J Clin Invest 105: 161-171) to evaluate gap junction function.
Cardiomyocytes are isolated from Dbh-1- and Dbh+1- mouse
embryos at E9.5-E10.5, cultured at various densities for 24
hours on collagen-coated glass coverslips, and subjected to
the dye-coupling assay. This involves loading fluorescent dye
intracellularly via a patch pipette and subsequently counting
the number of coupled cells obtained as a result of this treatment (defined as those that become obviously fluorescent
after dye injection).
Another experiment is to perform gene expression profiling using gene chip microarray analysis. The objective is to
determine if genes encoding for gap junction and other conduction cell proteins are influenced by catecholamines. The
rationale is that, if catecholamines influence differentiation of
conduction tissue, then Applicant may expect to see altered
patterns of conduction system markers in catecholaminedeficient hearts. RNAs are isolated from Dbh_;_ and Dbh+/sibling hearts at El0.5, and used for microarray analysis. This
strategy can evaluate how the absence vs. the presence of
endogenous catecholamines affects gene expression in the
heart. The expression of specific genes as well as patterns of
gene expression (cluster analysis) can be evaluated essentially as described above.
Specific Methods
Double immunofluorescent histochemical stammg and
whole-mount ~-galactosidase staining is performed as
described above in Example 1.
Isolation of embryonic cardiac cells is performed as
described by Maltsev et al. (1999). Briefly, embryonic hearts
are isolated by surgical dissection and pooled in Hank's Balanced Salt Solution (Ca++/Mg++_free) on ice. The tissue is
then be pre-warmed to 37.degree. C., and transferred to prewarmed collagenase buffer containing 1 mg/ml collagenase B
(Roche) and the following (in mM): NaCl (120), KC! (5.4),
MgS04 *7H 2 0 (5), Pyruvic acid (5), Taurin (20), Hepes (10),
Glucose (20), and CaCl 2 (0.03), pH 6.9. Digestion proceed at
37.degree. C. with intermittent swirling for 30 mins. Collagenase digestion is terminated by the addition of KB buffer
consisting of (in mM): KC! (85), K 2 HP04 (30),
MgS04 *7H 2 0 (5), EDTA (1), Mg 2 ATP (5), Pyruvic acid (5),
Creatine (5), Taurin (20), and Glucose (20), pH 7.2. The tissue
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is mechanically dissociated by subjecting it to mild rocking
for 30 mins. Final dissociation is achieved with mild trituration. Single cells are collected by passing the material through
sterile 70 µm mesh filters to remove clumps and other debris.
The cells can then either be seed onto collagen-coated coverslips for whole-cell patch-clamp analysis, or then can be
further separated into fluorescent and non-fluorescent cardiac
cells using FACS.
Action Potential Recordings can be performed as below:
1) Conventional Microelectrodes
Conventional microelectrodes having tip resistance in the
range ofl 5-25 megaohms are pulled on a horizontal micropipette puller (Model P-87, Sutter Instruments Co., Novato,
Calif.) from TW120F glass (WPI, Sarasota, Fla.) and filled
with 3 M KC!. Microelectrodes are coupled to an electrometer (model 750, WPI, Sarasota, Fla.) whose output is connected to a conditioning amplifier (Meca, Indianapolis, Ind.)
that allows both amplification and electronic derivation of
voltage with respect to time. The dual voltage outputs of this
recording amplifier are connected to an oscilloscope with
dual sweep capability (Tektronix, model 5B12N) and an
IBM-AT compatible Pentium II computer with a fast AID
board and analysis software (APES, Hugo Sachs Elektronik,
March-Hugsgetten, Germany). Applicant's analyses include
measurement of the resting membrane potential, upstroke
velocity, amplitude, and duration (APD50 andAPD90) of the
action potentials recorded from analogous regions of wildtype and Pnmt knockout embryonic mouse hearts.
2) Optical Measurements with Voltage-Sensitive Dyes and
Photodiode Array Detection
Imaging with voltage-sensitive dye (VSD) provides submillisecond temporal resolution for examining the synchronization among heart tissue or cultured heart cells. In cultured
cells, the sensitivity of the method permits resolution of
single action potentials from individual neurons. Thus, the
diversity in conductance and the shape of the action potential
in the cell population can also be examined. Staining: Heart
tissue slice or cultured dissociated cells are incubated for 30
to 60 min in ringer solution containing 0.05 mg/ml of the
voltage-sensitive dye Di4-ANEPPS (Molecular Probes,
Eugene, Oreg.). The ringer is gently stirred and bubbled with
carboxygen and kept at 27-32.degree. C. During this staining
period, some dye molecules diffuse to the cell membrane and
bind to the lipid bilayer. This dye does not penetrate into the
cell. Although the staining is not selective to the cardiac
muscle cells, only excitable membrane can generate signal
(color change) and dye stained on the connective tissue only
contributes to the background fluorescence. The stained
preparation is perfused with a warm (34-37 .degree. C.), oxygenized Ringer on the stage of an upright microscope. The
image of the cells is projected onto a photodiode array, and the
dye molecules binding to the membrane convert the transmembrane potential change into the changes in fluorescence
intensity. The photocurrent produced by the fluorescent light
thus is linearly correlated to the trans-membrane potential of
the cells. Optical imaging is performed with a 124-element
photodiode array (Centronics Inc., Newbury Park, Calif.) at a
frame rate of 1,000 frames/second. A 5x (NA. 0.12, Zeiss)
objective is used to project the image of the preparation onto
the array where each photodetector receives light from a
0.33x0.33 mm2 area of the slice. The photocurrent of dyerelated fluorescent signals (at wavelength of 650 nm) from
each photodetector are individually amplified through a two
stage amplifier system. The amplifiers perform a current to
voltage conversion using a feedback resistor of 1 G-ohm, and
then a voltage gain of 1000, and a high-pass filter with a
time-constant of 1 sec (0.16 Hz comer frequency). The pho-

tocurrent from the photodiode is about 100 pA. The optical
signal size (dF/F) was about lx10- 2 to 5x10- 3 of the resting
fluorescent intensity. Optical recording trials are usually 20
seconds long, and 30-50 trials are recorded to limit the total
exposure time to less than 100 seconds for each preparation.
Signals from the photodiode array and two local field potential electrodes are digitized with a 12-bit data acquisition
board (Micro star Laboratories, Bellevue, Wash.) installed in a
PC. Before digitization, a 4-pole Bessel analog low-pass filter
with a 333 Hz corner frequency is applied to all optical
channels to ensure that the frequency of the analog signals
was lower than the Ny quest frequency of the sampling. Digitized data is directly transferred to the hard disk of the computer for subsequent analysis.
Whole cell voltage-clamp recording-Voltage-clamp
studies are performed essentially as described in the preprint
article by Katchman et al. (JPET, 2002). The specific protocols for individual current evaluations are provided below:
1) IKrinwardly rectifying background K+ current-The
inward-rectifier potassium current OKI) is elicited by command pulses (500 msec duration) from a holding potential
-40 m V (to inactivate sodium channels) to between -100 m V
and +40 m V at increments of 10 m V. The interval between
pulses are 10 seconds.
2) IK-delayed rectifier K+ currents OKs and IKr)-The following protocol is used to evaluate the slow component of the
delayed-rectifier potassium current OKs). A 7 .5 sec test pulse
is delivered from a holding potential of -40 m V to +40 m Vin
10 m V increments in the presence of the selective IKr blocker,
E4031 (1 µM), and tail currents are measured upon repolarization to -40 m V. The rapid component of the delayed rectifier, IK" is measured as the E4031-sensitive difference current using the same protocol except that the duration of the
pulse is 1.5 seconds ratherthan 7.5 seconds. In both cases, the
interval between pulses is 20 seconds. The I-V relationships
for IK are constructed by measuring tail currents as previously
described (Liu et al., 1998, J Pharmacol Exp Ther 285:672679; Liu et al., 1998, J Pharmacol Exp Ther 287:877-883).
3) I;-hyperpolarization-activated (pacemaker) current-To
evaluate Ifl Applicant uses a modification of the protocol
described by Difrancesco et al. (J Physiol 1986, 377:61-88).
Briefly, the holding membrane potential is clamped at -40
m\7, and long (up to 1.5 seconds) hyperpolarizing pulses in
increments of 10 m V are applied from holding potential level
up to -130 m V. Applicant considers Ifto be present in a given
cell ifApplicant observed a cesium-sensitive, time-dependent
inward current. These observations are confirmed by blocking the current with the I_rspecific inhibitor, ZD7288. I-V
relationship is obtained by plotting tail current amplitude
versus the tail step potential. The steps (-70 to +10 m V, in
increments of 10 mV) are applied following the hyperpolarizing step to -120 mV to maximally activate If' Reversal
potentials and current densities are evaluated as described
above.
4) !Na-fast inward sodium current-The voltage dependence of activation ofINa is examined using -110 to -90 m V
holding potentials. Test pulse of 25 msec duration is applied
in increments of 10 mV from -100 to +80 mV. The steadystate inactivation (availability) curves are constructed using a
25 msec test pulse to -30 mV preceded by conditioning
pulses from -120 to +20 mV (in 10 mV increments), and
(Na+) are symmetrically set at 5 mM. In these experiments
high TEA internal and external solutions are used. Calcium
currents are blocked by using either nifedipine (1 µM) or
100-200 µM Cd2 +, and low concentrations (200 µM) of Ca2 +.
5) Ica,L-L-type calcium Ca 2 + current-The L-type calcium current is measured as described previously (Liu et al.,
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1998, J Pharmacol Exp Ther 287:877-883) by holding the
membrane potential at -60 to -40 m V to inactivate the
sodium current. In addition, TTX (10 µM) is used in some
experiments where more negative voltages are required as
holding potentials. To examine the voltage-dependence and
kinetics oflca,L, 100-200 ms test pulses from -60 to +80 m V
in 10 m V increments are applied. The kinetics of inactivation
of this channel are analyzed quantitatively when either Ca 2 +
or Ba 2 + are the charge carriers through the channel to determine both the Ca 2 +-induced and voltage-mediated components of the inactivation process. The voltage-dependence of
steady-state inactivation (availability curves) is constructed
using 500 ms conditioning pulses between -100 to +80 m V
(given in 10 m V increments from a holding potential of -60
m V) followed by a 100 ms test pulse to 0 m V. Recovery from
inactivation and its voltage-dependence is also examined by
varying the recovery interval between the test and conditioning pulses at different holding potentials. All solutions have
high concentrations of Cs+ and TEA, but contain no Na+.
Ica,L is studied both in the basal state (i.e., no added cAMP)
and in the fully phosphorylated state (200 µM cAMP) of the
channel.

differentiate into cells other than myocytes in the heart. This
experiment is important for determining the full potential of
cardiac Pnmt+ cells in vivo.
Applicant uses dual immunofluorescent and XGAL histochemical staining techniques to identify and map the
expression patterns of Pnmt+ cells and their descendents in
fixed mouse heart sections. These experiments are performed
largely as described above except that additional cell typespecific antibodies are included to determine if Pnmt+ cells
give rise to any non-myocyte cell types in the heart. A summary of the representative antibodies that are employed for
this analysis is listed in Table 5. Additional cell type-specific
antibodies are available for each of the cell types listed. The
immunofluorescent staining analyses are performed in conjunction with XGAL histochemical staining. Confocal laserscanning fluorescence microscopy is used in combination
with bright-field microscopy to visualize cellular and subcellular patterns of expression for these markers in the developing heart.
TABLE-US-00005 TABLE 5 Examples of Cell Type-Specific Antibody Markers Available for Co-Staining Experiments. Cell Type Antibody Marker Source References Striated Muscle Sarcomeric a-actinin* Sigma-Aldrich Ebert &
(St. Louis, Mo.) Thompson, 2001 Smooth Muscle a-Smooth
muscle actin Pacemaker Cells HCN4* Chemicon (SAN and
AYN) (Temecula, Calif.) Intrinsic Cardiac PNMT* ChemiconAdrenergic (ICA) Cells (Temecula, Calif.) Cardiac Stem
Cells c-Kit* Santa Cruz Biotech (Santa Cruz, Calif.) Epicardial Cells a4-integrin Santa Cruz Biotech (Santa Cruz, Calif.)
Endocardial Cells PECAM Cardiac neurons Choline SigmaAldrich Acetyltransferase* (St. Louis, Mo.) (ChAT) Fibroblasts Prollagen I *Antibodies that Applicant has tested in
published (Ebert & Thompson, 2001; Ferreira et al., 2001)
and preliminary studies.
Applicant focuses on three age groups for this experiment:
(1) Neonatal (PO-P4); (2) Young Adult (8-10 wks); andAged
(> 1.5 yrs). Applicant has already completed most of the prenatal analysis. Most of the work is done with neonates to
make the most efficient use of time and resources. The structure of the neonatal heart is similar to that of adults, yet its
smaller size means that less reagents (primarily antibodies)
are needed to perform this experiment than would be used for
adult sections. Applicant has already tested about one-half of
the antibodies listed in Table 5 (see asterisks) in neonatal
mouse hearts, but Applicant has not yet looked specifically at
non-myocyte markers that may identify Pnmt descendents as
neuronal, epicardial, endocardial, smooth muscle, or fibroblast cells. Once the staining is done in neonates, more limited
testing in adults is performed to determine if the pattern of
staining is fundamentally different from that observed in the
neonate.
One aspect of adult hearts that is different from neonates is
that the development of the intrinsic cardiac nervous system
is still immature in neonates, but is fully developed in the
adult. Applicant carefully examines Lacz expression in cardiac neurons in adult hearts. As indicated from Table 5, Applicant uses an anti-ChAT antibody as a marker for cholinergic
neurons. Another neuronal marker that may be useful is an
antibody that recognizes the a 3 subunit of the neuronal nicotinic receptor (a 3 -nAChR). Another method that should
prove useful here is silver staining, which selectively identifies neurons. The silver staining technique is relatively inexpensive and easy to perform. It should be relatively straightforward to combine silver staining and XGAL staining in the
same sections. Thus, by using these different approaches
(immunofluorescent vs. histochemical staining), Applicant is
able to determine if Pnmt+ cells become cardiac neurons. The

Example 3
Molecular Imaging of Novel Cardiomyocyte Stem Cells
The goal of this Example is to test the hypothesis that
molecular and cellular imaging techniques identify, track,
and functionally assess a novel population of cardiomyocyte
stem cells for their potential to regenerate cardiac muscle
tissue in vivo. A schematic illustration of cardiomyocyte differentiation is shown in FIG. 13.
Applicant's data indicate that cardiac cells transiently
expressing the enzyme, Pnmt, ultimately become myocytes
that contribute substantially to pacemaking, conduction, and
working myocardium. Thus, Pnmt serves as a novel marker of
cardiomyocyte progenitor cells (Pnmt+ cells) in the developing heart. Applicant tests the idea that Pnmt+ cells can be
selectively isolated and transplanted into damaged cardiac
regions where they are monitored both physically (location)
and physiologically (function) in vivo using non-invasive
molecular and cellular imaging techniques. An exemplary
method is shown in FIG. 14. Four specific aims are described
as follows:
One aim is to determine the fate of Pnmt+ cells in the heart
using newly developed mouse genetic models and "conventional" cellular/molecular imaging techniques (immunofluorescent histochemical staining and confocal laser-scanning
fluorescence microscopy). This aim establishes the cellular
anatomical distribution pattern of Pnmt+ cells and their
descendents in developing mouse hearts.
One experiment is to determine the fate of Pnmt+ cells in
the heart using Pnmt-CrexR26R mice. This experiment tests
the hypothesis that cardiac Pnmt+ cells differentiate into myocytes in vivo. Applicant has already made substantial progress
in this area using the newly developed Pnmt-Cre mice. When
bred with R26R reporter mice, Pnmt-Cre activated Lacz
expression, thereby allowing Applicant to identify and map
descendents of Pnmt+ cells in the developing mouse heart
with XGAL staining. Applicant has examined embryonic,
fetal, and neonatal hearts. Applicant also examines adult and
aged hearts in similar fashion to determine if Lacz+ cells
persist and maintain the patterns of distribution noted in the
late fetal/early postnatal period. Further, Applicant uses additional cell type-specific markers to determine if Pnmt+ cells
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development, function, and regulation of the intrinsic cardiac
nervous system are not well understood. Consequently, this
experiment could shed new light on this relatively unexplored
aspect of cardiac development.
The experiments with the aged hearts is performed primarily to see ifthere is any loss or attrition of Pnmt+ cell descendents in the heart over time. These experiments are performed
on a limited basis unless major differences are noted between
aged, adult, and neonatal patterns of Lacz expression in the
hearts of these mice.
Based on the published and preliminary data, Pnmt+ cells
may primarily give rise to cardiomyocytes. Applicant anticipates that some of these cells may contribute to neural crest
derivatives in the heart since the preliminary data suggest that
Lacz+ neural crest cells may invade the heart in PnmtCrexR26R embryos. Moreover, the Pnmt+ cells that eventually populate the adrenal medulla are known to be derived
from migrating neural crest cells. Thus, there is precedence
for a neural crest origin of Pnmt+ cells in other tissues, and it
is certainly possible that this is also true in the heart. Thus,
Applicant carefully examines Lacz expression in these hearts
to see ifit is consistent with known patterns of neural crest cell
distributions in the heart (e.g., outflow tract septum). Since
cardiac neurons are also thought to arise from neural crest,
Applicant may expect to see some co-staining for Lacz and
neuronal markers such as ChAT.
Another experiment is to identify Pnmt+ cells in the heart
using Pnmt-nEGFP knock-in mice. To develop a "tag" for
living Pnmt+ cells in mice, Applicant has created a new line of
Pnmt knock-in mice that express a nuclear-localized
Enhanced Green Fluorescent Protein (nEGFP) reporter gene
from the endogenous Pnmt gene locus. Applicant hypothesizes that Pnmt+ cells express nEGFP in these mice, and
Applicant tests this hypothesis by analyzing fixed tissue sections for nEGFP expression using confocal laser-scanning
fluorescence microscopy. The specificity of nEGFP expression in this newly developed model is validated.
Applicant validates the new Pnmt-nEGFP knock-in model
by first showing that insertion of the nEGFP reporter effectively disrupted the expression of the endogenous Pnmt gene.
Two independent assays are performed to accomplish this
goal. First, Applicant measures epinephrine and norepinephrine concentrations in the adrenal glands, heart, and blood
from wild-type (Pnmt+1"'), heterozygous (Pnmt+lnEGFP) and
homozygous reporter (PnmtnEGFP!nEGFP) mice using a standard radioimmunoassay, as Applicant has described previously (Ebert & Thompson, 2001, supra]. Second, Applicant
compares nEGFP expression in various tissues (adrenal
glands, heart, etc.) with endogenous Pnmt expression using
immunofluorescent histochemical staining methods.
To confirm and extend the findings from the experiments
with Pnmt-CrexR26R mice, Applicant examines co-expression of nEGFP with the various cell type-specific antigens
listed in Table 5, by using immunofluorescent histochemical
staining. nEGFP expression is identified by direct fluorescence emission (green) from the nEGFP reporter protein
while co-staining is performed with immunofluorescent histochemical techniques using red fluorescent (Texas Red or
TRITC) secondary antibodies.
Applicant expects to find that nEGFP expression is
restricted to Pnmt+ cells in vivo, and that homozygous knockin reporter (Pnm~EGFP!nEGFP) mice do not express endogenous Pnmt or produce epinephrine. In contrast, wild-type
(Pnmt+1+) and heterozygous (Pnmt+lnEGF~ mice are
expected to express Pnmt and produce normal levels of epinephrine (as was true for Pnmt-Cre mice). Such results would
help to confirm the specificity ofthetargetednEGFP insertion

into the endogenous Pnmt gene locus as well as the potential
usefulness of the nEGFP reporter as a viable marker for
Pnmt+ cells. Since Applicant has already demonstrated that
another Pnmt knock-in gene, Pnmt-Cre, was expressed specifically as expected in vivo, Applicant expects that nEGFP
expression displays a similar pattern of specificity, especially
with respect to the ICA cells in the developing heart and the
chromaffin cells in the adrenal medulla. Pnmt is normally
expressed in limited numbers of cells in various other tissues
including brainstem and retinal neurons, lung, spleen, thymus, and testes.
In certain cases, Applicant is able to use the recombinant
Pnmt-nEGFP ES cells to generate cardiomyocyte progenitor
cells by inducing them to differentiate into beating cardiac
cells in vitro. For the purpose of this project, generation of
Pnmt-nEGFP mice is not necessary, but would certainly help
provide confidence in the fidelity of this targeted reporter
gene. In addition, the mice could provide an alternative
source of cardiomyocyte stem (Pnmt+) cells (e.g., instead of
cardiac-differentiated recombinant ES cells) for the transplantation experiments described for the latter aims. One
attractive alternative to Pnmt-nEGFP expression as a reporter
would be expression of a unique cell surface marker gene
from the Pnmt locus. Applicant could then use fluorescentlytagged antibody strategies to identify the cells and mark them
for isolation using FACS. There are many potential marker
genes that could be tested as such.
Another aim is to isolate and characterize living cardiac
Pnmt+ cells in vitro using fluorescence-activated cell sorting
(FACS) and magnetic microsphere particle loading techniques. This aim focuses on optimizing methods for isolating
Pnmt+ cells and loading them with magnetic microsphere
particles for subsequent transplantation and in vivo imaging
analyses.
One experiment is to isolate Pnmt+ cells from cardiacdifferentiated Pnmt-nEGFP recombinant ES cells. Applicant
plans to take advantage of nEGFP expression from the endogenous Pnmt gene locus to identify and isolate presumptive
cardiomyocyte progenitor (Pnmt+) cells from other types of
cardiac precursor cells using FACS. This strategy may provide a means to selectively obtain a novel population of
cardiomyocyte stem cells that are evaluated in the transplantation experiments described above.
Applicant initiates cardiac differentiation in Pnmt-nEGFP
ES cells using the "hanging ball" method. The process takes
7 days to form embryoid bodies that are then transferred to
tissue cultureware for attachment. Beating activity develops
in the focal adhesion plane over the next few days (e.g., 7+1,
7+2, 7+3 days). Neither the endogenous Pnmt gene nor the
Pnmt-nEGFP gene was expressed in undifferentiated ES
cells, but both were activated during cardiac differentiation.
Endogenous Pnmt mRNA was readily detected at 7+1 and
7+3 days, in strong concurrence with the abundant appearance of nEGFP+ cells at these stages in cardiac-differentiated
Pnmt-nEGFP ES cells. These cardiac-differentiated ES cells
can be dispersed into single cells using published methods
that Applicant has successfully employed. The next step,
therefore, is to isolate these cells from non-EGFP+ cells using
FACS.
Applicant expects to selectively recover EGFP+ cells from
a dispersed population of semi-differentiated ES cells.
Although Applicant may ultimately need fewer or more cells
for the transplantation experiments, Applicant uses this range
(XX-YY) as an initial benchmark for the number of EGFP+
cells needed for each transplantation experiment. Because
mouse ES cells can be readily expanded and differentiated in
culture, it is not unrealistic to achieve yields in this range.
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Indeed, Zandstra et al. [2003] recently demonstrated "Scalable production of ES cell-derived cardiomyocytes" using a
similar FACS-based strategy. Thus, it appears feasible to
obtain sufficient numbers of cells using this strategy.
Another experiment is to isolate Pnmt+ cells from embryonic mouse hearts (Pnmt-nEGFP mice). A potential limitation of ES cells is that they may differentiate into non-cardiac
as well as cardiac cells. Applicant aims to overcome this
limitation by selecting Pnmt-nEGFP+ cells from cardiac-differentiated ES cells, but Applicant cannot be certain that all
nEGFP+ cells isolated in this manner are cardiac-destined.
Indeed, Pnmt is also expressed in neurons, chromaffin cells,
and other types of cells that could conceivably "contaminate"
the ES cell preparations. To minimize this concern, Applicant
also isolates Pnmt-nEGFP+ cells from embryonic/fetal
mouse hearts for use in the subsequent transplantation experiments described above.
Applicant uses essentially the same strategy as described
for the previous experiment except that Applicant's source
material includes embryonic and fetal hearts from transgenic
Pnmt-nEGFP knock-in mice. Applicant expects that PnmtnEGFP+ cells isolated from embryonic/fetal hearts and cardiac-differentiated ES cells behave similarly in subsequent
differentiation and transplantation experiments. By comparing Pnmt-nEGFP+ cells obtained from these two different but
related sources, Applicant is able to determine if there are
significant differences in the differentiation/transplantation
potential of these cell populations.
Another experiment is to perform clonal analysis of PnmtnEGFP+ cells. To characterize the differentiation potential of
Pnmt-nEGFP+ cells isolated from cardiac-differentiated ES
cells and embryonic/fetal hearts, Applicant analyzes clonal
colonies of nEGFP+ and non-fluorescent kindred cells
obtained during preparation of the cells. Applicant hypothesizes that nEGFP cells differentiate into cardiomyocytes and
cease to express nEGFP. By immunofluorescent cytochemical staining of clonal populations with cell type-specific antibody markers (Table 5), the fate ofEGFP+ vs. EGFP cells can
be determined. This analysis may also provide a means to
optimize culture conditions for production of cardiomyocyte
stem cells for subsequent transplantation and molecular
imaging experiments.
Applicant disperses cardiac-differentiated recombinant
Pnmt-nEGFP ES cells and embryonic/fetal mouse hearts carrying the Pnmt-nEGFP knock-in transgene into single-cell
suspensions, and culture them at a density of .1 toreq.1 cell per
well in a 48-well culture dish containing a round glass coverslip. The coverslips be coated with different types of extracellular matrix materials (laminin, collagen, fibronectin,
matrigel, etc.) to determine if any of these treatments influences the differentiation and growth potential of the seeded
cells. Immediately after seeding, each well is examined and
scored forthe presence or absence of an EGFP+ or EGFP- cell
by careful (manual) inspection using fluorescence microscopy. Each well is similarly examined on a near-daily basis
for 2-3 weeks. Any signs of myocardial development (striations, contractions, etc.) are duly noted. At the end of this
visual inspection period, Applicant fixes the cells on the coverslips and subject them to immunofluorescent cytochemical
staining using cell type-specific antibodies (Table 5) to determine which cardiac cell types, if any, emerge from this clonal
expansion in culture.
Applicant anticipates that at any given stage of cardiac
development, there is a heterogeneous mixture of heart-like
cells representing many different stages of development and
differentiation. Thus, Applicant expects that some nEGFPcells may become nEGFP+ if they represent an early stage of

cardiac or pre-cardiac stem cells. Conversely, Applicant also
expects that some nEGFP- cells do not differentiate into
nEGFP+ cells because they have already proceeded through
the cardiomyocyte stem (CMS) cell stage of development or
because they have differentiated along a different pathway or
not at all. This analysis, while tedious, can be a very powerful
tool for determining differentiation potentials of individual
cells discriminated by their ability to express nEGFP from the
Pnmt gene locus.
Another experiment is to perform magnetic particle-loading of Pnmt-nEGFP+ cells in vitro. To track the position of
transplanted cells in vivo using MRI, Applicant pre-loads
them with magnetic particles in vitro. Demonstration that
Applicant can specifically isolate nEGFP+ cells pre-loaded
with magnetic particle beads would set the stage for the
transplantation and molecular imaging experiments.
Applicant induces cardiac differentiation in recombinant
Pnmt-nEGFP ES cells. After the embryoid bodies are placed
onto culture plates (day 7), they are overlaid with polymercoatedmagnetic micro sphere particles for 24-48 hours. At the
end of this incubation period, Applicant removes the media
and disperse the cells for FACS isolation. The FACS isolation
method can be modified to allow selective isolation of cells
that have green fluorescent nuclei (due to nEGFP expression
from the Pnmt locus) and red fluorescent cytoplasm (due to
the presence of Dragon Red polymer-coated magnetic microsphere particles). A subset of these cells is fixed onto coverslips for photo-documentation of particle loading using dual
fluorescence microscopy.
Since these magnetic micro sphere particles have been successfully used to pre-load mouse ES cells as well as several
other types of cells in culture, Applicant expects that they also
effectively pre-load Pnmt-nEGFP+ cells. An obvious potential difficulty is that Pnmt-nEGFP+ cells may not take up the
particles efficiently or that Applicant is unable to isolate sufficient numbers of particle-loaded cells to effectively evaluate
MRI tracking of these cells once transplanted. It is apparent,
however, that if the cells are loaded with the particles, then
they are relatively easy to track by MRI. Nevertheless, if
Applicant has difficulty loading these cells using the strategy
outlined above, Applicant isolates the nEGFP+ cells by FACS
first, and then load them with the particles. This would have
the advantage of enriching the population of cells to be loaded
with the desired type of cells (Pnmt-nEGFP+) for the subsequent transplantation and molecular imaging experiments.
Another alternative strategy would be to load the cells with
different types of magnetic particles. Optionally, Applicant
may simply load cardiac-differentiated cells en masse. Cells
pre-loaded with magnetic particles are separated from free
particles using Percoll gradients, as previously described.
Another aim is to identify and track cardiac Pnmt+ cells in
vivo using magnetic resonance imaging (MRI) techniques
following transplantation of these cells into regions of the
mouse heart damaged by myocardial infarction (MI) or
cryoablation. This aim determines if Pnmt+ cells persist in the
heart following transplantation into damaged hearts and if so,
whether or not cardiac performance is improved as a result of
this intervention.
One experiment is to tracking transplanted cardiomyocyte
stem cells using MRI. Applicant hypothesizes that cardiomyocyte stem cells transplanted into damaged regions of the
heart facilitate repair and regeneration of the damaged cardiac
tissue. Thus, the transplanted cells may remain near the site of
transplantation and ultimately contribute to new myocyte
formation in the damaged regions. This, in turn, should lead to
improved cardiac performance. As a first step towards testing
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this hypothesis, Applicant identifies and track the location of
of these cells (indicating that Pnmt-nEGFP expression had
the transplanted cardiomyocyte stem cells in vivo using MRI.
been shut down during differentiation of the transplanted
Cardiomyocyte stem cells (Pnmt-nEGFP+ or similar cells)
CMS cells in vivo). Further, if the transplanted cells have
are pre-loaded and isolated as described above. These cells
differentiated into myocytes, then Applicant expects that cells
are delivered to a region of the heart damaged by experimencontaining the fluorescent magnetic particles express myotally-induced myocardial infarction (MI). For controls,
cyte-specific markers such as sarcomeric a-actinin. Finally,
Applicant performs mock transplantations and transplantaApplicant expects to see significant thickening of muscle
tion of non-selected cardiac-differentiated ES cells pretissue in the infarcted region of hearts receiving transplanted
CMS cells relative to control hearts that did not receive transloaded with magnetic microsphere particles. Applicant performs the transplantations at various times post-MI to 10 plants.
determine if there is an optimal window of opportunity for
Another aim is to assess the myocyte differentiation potential of Pnmt+ cells in vivo using bioluminescence imaging
this type of cell-based intervention. In addition, Applicant
(BLI) techniques following transplantation of transgenic
also varies the number of cells used per transplantation to
determine what the optimal number of these cells is for this
myocyte-specific promoter-luciferase reporter cells into
purpose. In each case, the transplanted cells are identified and 15 regions of the mouse heart damaged by MI or cryoablation.
This aim determines if transplanted Pnmt+ cells differentiate
tracked in vivo over a period of at least several days, and
into specific types of myocytes in vivo by evaluating
possibly weeks or months ifthe cells/signal persists. The MRI
results may show that the transplanted cardiomyocyte stem
luciferase reporter gene expression over time using BLI techcells remain in the heart at or near the region damaged by the
niques.
infarction.
20
One experiment is to perform bioluminescent imaging of
One alternative strategy that could prove beneficial here is
transplanted recombinant ES luciferase reporter cells. The
the use of more localized cryoablation damage rather than MI
rationale is that if transplanted cardiomyocyte stem cells difdamage, which can affect a relatively larger portion of the
ferentiate into myocytes in vivo, then they should begin to
heart. There may be some advantage in trying to repair/rerobustly express myocyte-specific genes. This expression can
generate a smaller region of damage. An additional advantage 25 potentially be monitored in vivo using BLI to identify and
of cryoablation is that Applicant may be able to target more
quantify luciferase reporter expression driven from a strong
specific areas such as pacemaker myocytes in the SA node.
well-characterized myocyte-specific promoter. Applicant
Since Applicant has shown that Pnmt+ cells developmentally
uses the cardiac a-myosin heavy chain (aMHC) promoter
contribute to pacemaker myocytes, this would be an attractive
fused to a luciferase reporter gene to create a new recombi30 nant ES cell line derived from recombinant Pnmt-nEGFP ES
model to analyze for this project.
Another experiment is to perform functional assessments
cells. Applicant then tests the resulting stably transfected
of cardiac performance in damaged hearts following transclones for their ability to express luciferase in undifferentiated vs. cardiac-differentiated ES cells.
plantation of cardiomyocyte stem cells into the damaged
Applicant expects that luciferase expression is low or
regions in vivo. Applicant hypothesizes that cardiac performance is improved following transplantation of cardiomyo- 35 absent in undifferentiated ES cells, but is strongly activated
and sustained once the cells differentiate into myocytes.
cyte stem cells into damaged regions of the heart. Applicant
Since Applicant has previously shown that there is an inverse
primarily uses MRI to perform these assessments, which can
relationship between cardiac Pnmt expression and myocytebe done in parallel with the MRI tracking experiment
specific expression (Ebert & Thompson, 2001, supra), Applidescribed above. Heart rate/rhythmicity and left ventricular
ejection fraction is measured as the endpoints for this experi- 40 cant also predicts that Pnmt-nEGFP+ cells are not substantially express luciferase, at least until Pnmt promoter activity
ment. Applicant compares cardiac performance in MI mice
(and the resulting nEGFP expression) begin to shut down as
that received cardiomyocyte stem cell transplants vs. those
myocyte differentiation proceeds. Thus, upon transplantation
that did not (mock transplants). Normal (non-MI) littermates
of these recombinant (Pnmt-nEGFP/960 MHC-Luc) ES cells
serve as an additional control group.
Another experiment is to perform postmortem histological 45 into infarcted or ablated regions of the mouse heart, Applicant
assessment of damaged/repaired cardiac regions. If repair of
expects Pnmt-nEGFP expression to decline and aMHC-Luc
damaged tissue occurs as a result of cardiomyocyte stem cell
to increase as an indicator of myocyte differentiation in vivo.
One alternative would be to transplant ES cells that had
transplantations, then Applicant expects to see some evidence
of regeneration by examining the damaged region using hisalready differentiated into myocytes, and hence, would
tological methods. At the termination of the MRI tracking 50 already be expressing high levels of aMHC-Luc. The main
experiment, the mouse is humanely sacrificed and the heart is
difference between this strategy and the primary strategy is
fixed, processed, and sectioned for histological assessment.
that Applicant would not pre-select Pnmt-nEGFP cells by
To determine the location of the transplanted cells and their
FACS prior to transplantation. In other words, the ES cells are
descendents (if present), Applicant looks for cells harboring
differentiated into beating cardiac cells, dispersed, collected
the fluorescent magnetic particles (Dragon Red) that were 55 and transplanted en masse into damaged hearts. This should
provide a "maximum" luciferase signal from these cells for
loaded into the cells prior to transplantation. These assessBLI. If this alternative strategy now permits detection of
ments are combined with immunofluorescent histochemical
luciferase activity from the heart in vivo using BLI, then this
staining techniques using cell type-specific antibodies (Table
would suggest that Applicant is primarily dealing with an
5) to determine if the transplanted cells differentiated into
myocytes or some other type of cardiac cell. In addition, 60 issue of BLI sensitivity. Applicant also considers using a
Applicant measures the size of the infarcted region from
different myocyte-specific promoter such as cardiac actin or
sarcomeric a-actinin.
control and transplanted hearts using morphometric methods.
Applicant expects that the transplanted cells remain in the
Another alternative would be to sacrifice the animals at
heart where they predominantly become myocytes. Thus,
various times post-transplantation, and assay cardiac protein
Applicant expects to find cells that have red fluorescent beads 65 extracts for luciferase activity. Such method would be a powin the cytoplasm (marking transplanted cells and their progerful and straightforward method for determining if there was
eny), with little or no green fluorescence retained in the nuclei
any increase in luciferase expression following transplanta-
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tion. If Applicant observes significant increases in aMHCLuc activity in these extracts over time, then this would also
point to a sensitivity issue for the BLI measurements. If, on
the other hand, little or no luciferase activity is produced from
transplanted heart extracts, then this would indicate that the
transplanted cells are probably not differentiating into myocytes. In either case, these results are supported by the histological assessments described in the previous experiment.

Consistent with this idea, acute treatment of spontaneously
beating myocyte cultures with either the al-selective antagonist, prazosin, or the ~-selective antagonist, timolol, led to
dose-dependent decreases in the beating rate within seconds
after drug application (FIG. 16). Significant slowing (-25%
decrease) in the beating rate was observed in the presence of
1 µM prazosin (p<0.01, n=l 0). When the prazosin concentration was increased to 10 µM, severe depression (>85%
decrease) in the beating rate occurred. Timolol also caused
significant concentration-dependent slowing in the beating
rate (p<0.01, n=6). These results show that application of
either al- or ~-adrenergic receptor blockers lead to concentration-dependent slowing of beating rate.
To test the possibility that serum catecholamines may have
influenced our results, Applicant stripped the serum using
charcoal-treatment to remove any trace amounts of catecholamines that may have been present. Beating activity was maintained for at least 72 h after charcoal-stripping (FIG. 17). The
~-blocker timolol strongly suppressed beating activity under
these conditions, an effect that was fully rescued by the addition of epinephrine (FIG. 17). Similarly, application of the
al-blocker prazosin led to significant decreases in beating
rates (FIG. 18). The addition of the al-selective agonist,
L-phenylephrine, resulted in a dose-dependent reversal of the
prazosin-induced decrease in beating rate. These results show
that al- and ~-adrenergic receptor antagonists were effective
at blocking beating even in the absence of any potential influence from serum catecholamines.
2. Materials and Methods
A) Materials. All drugs and chemicals used for this study
were purchased from Sigma Chemical (St. Louis, Mo.,
U.S.A.). Drugs were prepared as concentrated stock solutions
and frozen in small aliquots at -SO.degree. C. The stock
aliquots were thawed immediately before use and were not
refrozen. Rabbit anti-PNMT and anti-DBH antisera have
been previously described (3). Mouse monoclonal anti-TH
and anti-sarcomeric a-actinin antibodies were purchased
from Sigma Chemical. FITC-conjugated donkey anti-rabbit
and TRITC-conjugated donkey anti-mouse secondary antibodies were obtained from Jackson Immunoresearch (West
Grove, Pa., U.S.A.).
B) Animals. Timed-pregnant Sprague-Dawley rats were
obtained from Taconic Farms (Germantown, N.Y., U.S.A.).
Neonatal pups were used within the first 2 d after birth. All
experiments were conducted in strict concordance with the
guidelines provided by the Georgetown University Animal
Care and Use Committee and the National Institutes of
Health.
C) Immunofluorescent histochemical and cytochemical
staining. Double immunofluorescent staining of neonatal rat
hearts and cardiomyocyte cultures was performed essentially
as described previously (3). For immunofluorescent
cytochemical staining of cultured cardiomyocytes, the myocytes were seeded onto collagen-coated coverslips (12 mm
round) at the time of isolation, and allowed to grow in culture
for 7-9 d before fixation. To fix the cells, the culture medium
was removed and the cells were rinsed twice with PBS. The
cells were then exposed to 4% paraformaldehyde in PBS for
15 min at room temperature. At the end of this fixation period,
the fixative was removed and the cells were washed twice
with PBS. The cells were then used immediately for immunofluorescent staining or stored in PBS in 4.degree. C. for
subsequent staining.
Because the anti-DBH and anti-PNMT antisera were produced in rabbits while the anti-TH antibody was produced in
mice, FITC-conjugated anti-rabbit (green fluorescence) and
TRITC-conjugated anti-mouse (red fluorescence) secondary

Example 4
Intrinsic Cardiac Catecholamines Help Maintain Beating
Activity in Neonatal Rat Cardiomyocyte Cultures
1. Results
To identify ICA cells in neonatal rat hearts, Applicant used
immunofluorescent histochemical staining techniques using
antibodies that specifically recognize the major catecholamine biosynthetic enzymes. Many brightly labeled fluorescent cells were identified using anti-PNMT antiserum. Costaining with an anti-TH antibody revealed an essentially
identical pattern of expression. These ICA cells were primarily found in the ventricular myocardium near the endocardial
surface, but were also observed sporadically throughout the
heart. A similar pattern of co-staining was observed when
Applicant used anti-DBH and anti-TH antibodies. Positively
labeled cells appeared bright, were roundish or triangular in
shape, and primarily displayed cytoplasmic staining patterns.
Thus, each of the three independent catecholamine biosynthetic enzyme (TH, DBH, and PNMT) antibodies selectively
labeled a highly similar subset of cardiac cells in neonatal rat
hearts.
To view these presumptive ICA cells in relation to cardiomyocytes, Applicant co-stained sections for PNMT and a
myocyte-specific marker, sarcomeric a-actinin. Individual
ICA cells were again identified in ventricular myocardium.
When co-stained for a-actinin, a characteristic ladder-like
sarcomeric pattern was evident in many myocytes. By superimposing the PNMT and a-actinin images, Applicant
obtained an "overlay" image where ICA cells can be visualized in direct juxtaposition to underlying myocytes. To identify ICA cells in primary cultures of neonatal rat cardiomyocytes, Applicant seeded the cardiomyocytes onto collagencoated coverslips and allowed them to develop into
synchronous rhythmic beating clusters of cardiomyocytes
over a 7-d period. The cells were then fixed and co-immunofluorescently labeled for PNMT and sarcomeric a-actinin.
PNMT staining was punctate and cytoplasmic, whereas a-actinin staining was evident in sarcomeric structures. The overlay image shows an ICA cell sitting atop a cluster of cardiomyocytes. ICA cells could also be identified in these
cultures by co-staining for DBH and TH. Although the relative abundance ofICA cells in these neonatal rat cardiomyocyte cultures was low (only -1 ICA cell/2xl05 myocytes),
these results nevertheless show that ICA cells were present
and that they were closely associated with cardiomyocyte
clusters.
To determine whether beating activity in culture was
dependent upon local catecholamine production, the wells
were treated with increasing concentrations of reserpine, a
catecholamine-depleting agent. Significant dose-dependent
decreases in beating rates were observed in the presence of
reserpine (FIGS. 15A and B). These decreases could be
largely reversed by the addition of norepinephrine (FIG.
15C). These results suggest that endogenous catecholamines
are needed for the maintenance of beating rates in these
cardiomyocyte cultures.
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antibodies were used to detect specific labeling ofDBH- (or
PNMT-) and TH-expressing cells, respectively. Applicant has
previously demonstrated the specificity of these antibodies
using immunofluorescent histochemical staining assays.
D) Preparation of rat neonatal cardiomyocyte cultures.
Neonatal rat cardiomyocytes were prepared according to
Simpson and Savion, 1982, Circ Res SO: 101-116, with the
following modifications: Neonatal rat pups were killed by
swift decapitation within the first 2 dafter birth. The heart was
immediately removed under aseptic conditions and placed in
ice-cold sterile HBSS (no ca++ or Mg++). Enzymatic and
mechanical dissociation of cardiomyocytes was then performed using the Neonatal Cardiomyocyte Isolation System
supplied by Worthington Biochemicals (Freehold, N.J.,
U.S.A.). The hearts were minced on ice and digested overnight at 4.degree. C. with purified trypsin (10 µg/mL) in
HBSS. On the following morning, the digested tissue was
transferred to a SO-mL conical tube and purified soybean
trypsin inhibitor (40 µg/mL) was added to terminate
trypsinization. The tissue was oxygenated and warmed to
37.degree. C. Purified collagenase (10 U/mL) was added and
digestion proceeded for 4S min at 37.degree. C. with intermittent gentle swirling. Mild trituration was then used to
mechanically dissociate the digested tissue, and single-cell
suspensions were obtained by filtering this digested material
through 70 µm sterile mesh filters. The cells were collected by
low-speed centrifugation. The supernatant was discarded and
the cell pellet resuspended in DMEM (high glucose, Biofluids, Rockville, Md., U.S.A.) culture medium containing 10%
defined iron-supplemented bovine calf serum (Hyclone
Laboratories, Logan, Utah, U.S.A.), 2 mM glutamine, and
gentamicin sulfate (SO µg/mL). In some experiments, the
serum was pretreated with charcoal before adding it to the
media (10% volume as above) to remove possible trace
amounts of catecholamines that may have been present The
cells were then "preplated" to remove fibroblasts, and the
remaining cells counted and seeded onto multi-well culture
plates at a density of7S,OOO cells per cm2 . The media was
changed every 2-3 d beginning the day after seeding. Bromodeoxyuridine (0 .1 mM) was added to the culture media for
the first 3 d to further minimize contamination from fibroblasts.
E) Beating rate measurements. Beating activity of cultured
cardiomyocytes was measured by edge-detection using photodiode sensors attached to a monitor screen depicting beating cells viewed by videomicroscopy. The entire microscope

was enclosed in a temperature-controlled (37.degree. C.),
custom-designed incubation chamber (Part numbers: 840000S, 8S06-0SO, and 8S37-02S; Coy Laboratory Products,
Inc., Grass Lake, Mich., U.S.A.) fed with S% C0i9S% air to
maintain constant pH. The photodiode sensor signal was filtered with an 8-pole Bessel low-pass filter (Model 900CT,
Frequency Devices, Inc., Havervill, Mass., U.S.A.) with a
cutoff frequency of 1000 Hz, and relayed to a PC equipped
with a National Instruments data acquisition board and LabView 4.0 processing software. Parallel outputs were also
directed to a Gould TASSO chart recorder and an oscilloscope.
Data were continuously acquired and stored to disk for later
analysis. Drugs were added and immediately mixed in the
media overlying the cells in each well. Predrug (baseline)
measurements were performed first, and the indicated drug(s)
were added as a 1OOx stock to the preexisting media on each
well, and rapidly mixed. Beating rates were remeasured
within 2-3 min after drug addition.
F) Data analysis. The number of beating rate measurements was typically obtained from different wells of multiwell plates (usually six wells per plate), seeded from the same
preparation of myocytes. Measurements were obtained
immediately before and after the addition of specified drugs.
In the reserpine experiment, beating rate measurements were
obtained at multiple time-points after drug administration.
Each experiment was replicated at least twice using independently isolated cultures, and a representative result from each
is shown. Unless otherwise indicated, all beating rate measurements were performed on cells that had been cultured for
7-9 d. All data are expressed as mean.+-.SEM. Statistical
significance was assessed by one-way ANOVA, with p<O.OS
required to reject the null hypothesis. Posthoc testing was
performed using Bonferroni's correction for multiple comparisons.
Incorporation by Reference
All publications and patents mentioned herein are hereby
incorporated by reference in their entirety as if each individual publication or patent was specifically and individually
indicated to be incorporated by reference.
While specific embodiments of the subject invention have
been discussed, the above specification is illustrative and not
restrictive. Many variations of the invention will become
apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention
should be determined by reference to the claims, along with
their full scope of equivalents, and the specification, along
with such variations.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 3
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 1
caggcgcctc atccctcagc agcc

<210> SEQ ID NO 2
<211> LENGTH, 24
<212> TYPE, DNA

24
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45
-continued
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer
<400> SEQUENCE, 2
ctggccagcg tcggagtcag ggtc

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 3
LENGTH, 32
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 3
ggtgtacggt cagtaaattg gacaccgtcc tc

The invention claimed is:
1. An isolated Phenylethanolamine N-methyltransferase
(Pnmt)-positive cardiac progenitor cell, wherein the cardiac
progenitor cell is committed to at least one cardiomyocyte
specific lineage selected from the group consisting of a pacemaker cell, a His bundle (HIS) cell, a Purkinje fiber (PUR)
cell, an atrial working myocyte, and a ventricular working
myocyte.
2. The isolated progenitor cell of claim 1, wherein the
progenitor cell is positive for a marker selected from the
group consisting of c-kit, Sca-1,and MDRl.
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30

3. The isolated progenitor cell of claim 1, wherein the
cardiomyoctye is a pacemaker cell selected from the group
consisting of a sinoatrial node (SAN) cell and an atrioventricular node (AYN) cell.
4. The isolated progenitor cell of claim 1, wherein the
progenitor cell is isolated from a tissue selected from the
group consisting of a developing heart and an adult heart.
5. The isolated progenitor cell of claim 1, wherein the
progenitor cell is isolated from a cultured stem cell line.
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